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INTRODUCTION 
              GDM is defined as ―glucose intolerance of variable degree with onset or first 
recognised during pregnancy‖. GDM was defined by O‘Sullivan in 1960 in a 
pregnant women group at Boston as a degree of glucose intolerance >2SD from mean 
on 100 grams glucose tolerance test.  Upto now the earliest known description about 
Gestational Diabetes Mellitus was written in 1824 by Henrich Benewitz for his 
doctoral thesis (Hadden, 1998). From that time, the concept of GDM has kindled 
keen interest amongst researchers and clinicians alike. Debate over the significance 
of Gestational Diabetes Mellitus, the efficacy and use and the need of screening for 
this condition and the impact of management on maternal and neonatal outcomes are 
clearly evident in the literature. As a consequence of this debate, no uniform 
guidelines for the management of GDM exist on a local, national or global level. 
Providing women with information to afford them the opportunity to make an 
informed decision about GDM also presents a challenge. 
Diabetes mellitus is a metabolic disorder in which a person, experiences high 
levels of blood glucose either due to inadequate (Type I)  insulin production or 
inadequate sensitivity (Type II). GDM is distinguished from diabetes mellitus with 
impaired musculoskeletal insulin sensitivity which occurs with pregnancy and has 
been recently reported to affect approximately 18% of pregnancies. The prevalence 
of diabetic status worldwide has increased significantly in the last few decades, 
reaching almost epidemic proportions in south Asia The increasing prevalence of 
gestational diabetes mellitus in developing nations is related to increasing 
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urbanization, reduced physical activity, modern changes in dietary habits and 
increased prevalence of overweight and obesity. According to World Health 
Organisation estimates, India has the largest number of cases of Diabetes in the 
world. As estimated 31.7 million people with diabetes in 2000 in India are projected 
to increase to 79.4 million in 2030
.1
 Women who are diagnosed with gestational 
diabetes have an increased chance (35% to 60%) of developing diabetes in the next 
1-2 decades and the predicted healthcare expenses are definitely going to be high. 
These costs will definitely be expected to increase. In a random survey performed in 
various cities in India in 2002-2003, an overall prevalence of GDM was observed to 
be
 
16.5 per cent. India unfortunately tops the listing of the countries with the largest 
numbers of people with diabetes (50.8 millions) in 2010 and is likely to remain so in 
2030 (87.0 million), if no drastic steps are taken to curb the epidemic In 1997 WHO 
estimated that the occurrence of diabetes in adult patients were expected to increase > 
120% from the 135 million people in 1990s to 300 million people in 2025. In 1970‘s 
reports of different Asian Indians who are living in the various locations of the world 
showed that they had higher prevalence of diabetes compared to other ethnic groups 
who are living in the same countries 
2
. A survey done in urban India in 1986 did not 
find any case of diabetes in less than 30 yrs of age
3
 but 15 yrs later, National urban 
Diabetes survey (2001) reported a prevalence of 5.4% in under 30 age group
4
. 
Another study done in Tamil Nadu, GDM was detected in rural areas with 9.9 % of 
women, 17 % of women in urban areas, and 13 % women in semi-urban areas.  WHO 
prevalence in India 16.55%.
5
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Many of these women were amenorrhoeic and only about 2% of diabetic patients 
conceived. The diabetic patients who conceived had an increased risk of morbidity 
and mortality.   
The major co-morbidities that are commonly associated with infants born to 
diabetic mothers are mainly hypocalcaemia, hypomagnesaemia, polycythemia,   
respiratory distress, growth retardation, hypoglycaemia, and and congenital 
malformations. With poor sugar controls in mothers 
 
perinatal outcomes are 
associated with 42.9% chances of mortality. With proper diagnosis and treatment of 
GDM, the perinatal and maternal outcome can be increased  
The proper measures taken for prevention will prevent or reverse this trend. 
The problem that happens during the critical period with intrauterine exposure of 
increased sugar levels has a negative impact on the pregnancy and it also leads to a 
situation of developing glucose intolerance in their latter period of life for the 
offspring. As of now, we don‘t have a proper national data for the presence of 
glucose tolerance in pregnant women.  
 Given the high rates of hyperglycaemia in pregnancy in most venues and the 
fact that selective testing based on known risk factors has poor sensitivity for 
detection of GDM among all members of a given population, universal rather than 
risk factor-based testing seems most practical. Universal testing is recommended by 
several organizations including International Association of Diabetes and Pregnancy 
study Group (IADPSG), Australian Diabetes In Pregnancy Study, Diabetes In 
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Pregnancy Study group India (DIPSI). 
 
Asian Indian women are considered to be at 
the highest risk of GDM and therefore anyway require universal testing. In India, 
approximately 27 million births occur annually requiring at least 27 million OGTTs 
annually; considering a 10% average prevalence of GDM, the number of GDM 
pregnancies would be around 2.7 million, a huge burden to deal with for any health 
system. Any recommendation for testing women for hyperglycaemia during 
pregnancy must, therefore, be pragmatic, feasible, convenient and cost-effective. 
 
 
 
 
 
 
 
 
 
 
 
                              
 
 
 
 
 
 
 
 
 
 
 Review of literature 
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REVIEW OF LITERATURE 
The review of literature of this study is being organized  under the following 
categories: 
 
1. historic persceptive 
2. carbohydrate metabolism during pregnancy 
3. physiology/pathophysiology 
4. effects of diabetes on pregnancy 
5. effects of diabetes on fetus: 
6. effects of pregnancy on diabetes mellitus 
7. terminology and classification 
8. screening methods 
9. literature review 
10. treatment options for gestational diabetes mellitus 
11. fetal surveillance and timing of delivery 
12. postpartum 
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1. HISTORIC PERSCEPTIVE: 
From the ancient time diabetes mellitus was discussed and described by 
Egypt‘s, Hindus and Greek‘s writings, dating back to age old 1500 BC, with a 
proper  evidence suggesting, some of these writings may have been copied from 
centuries earlier documents (3400 BC). The term diabetes in Greek means siphon, 
which was first coined by Aretaeus a Hippocrates disciple. William Cullen coined 
the Latin word for honey as ‗mellitus‘ in 1769, although, in the ancient literature 
Hindus coined the phrase ‗honey urine‘, (Sanders, 2002) noting that the urine 
attracted bees and flies. 
   
The first documented case study of Gestational Diabetes Mellitus was reported 
by Bennewitz in 1824, for his excellent doctoral presentation, in which he described 
the case of a young woman in her fifth pregnancy, which was complicated by newly 
diagnosed diabetes. The symptoms of the young woman‘s diabetes – unusual thirst, 
glycosuria and polyurea  which appeared along the due course of pregnancy.  
 
These problems resolved automatically following the birth of child, inspite of 
treatment with sweating, purging and applying leeches. The pregnancy resulted in 
birth of 12 pound stillborn boy fetus (Hadden, 1998). The  known description 
occured during 1883 where Mathews Dunccan belonging to Aberdden presented a 
review of 22 pregnancies which is complicated by diabetes mellitus  during a 
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discussion in the Obstetric Society of London (UK) and made the references to 
Benewitz‘s previous work (Haden, 1998). 
 
The term, Gestational Diabetes Mellitus, was first coined in 1951 by 
Peddersen (Vidaeff et al, 2003). 
 
Despite extensive research into this condition since the starting time, 
Gestational Diabetes Mellitus remains an area of debate and controversy.  (Brody, 
Harris & Lohr, 2003;Langer et al, 2005;, Vidaef et al, 2003).  
 
The most recent research relating to Gestational Diabetes Mellitus, endeavours to 
address various aspects of the debate by determination of corelation with maternal 
hyperglycaemia and increased adverse pregnancy outcome risks (Hyperglycemia and 
Adverse Pregnancy Outcome (HAPO) study cooperative group, 2008) and 
ascertaining whether treatment of the condition can reduce perinatal morbidity 
(Crowther ett al, 2005). Early researchers into the understanding of Gestational 
Diabetes Mellitus were highly interested in the prediction of identifying women who 
may subsequently develop Type 2 diabetes mellitus rather than the impact of the 
condition on the pregnancy and birth (O‘Sulivan & Maahan, 1964). However, the 
evidence that are demonstrating, increased maternal and neonatal comorbidities that 
are associated with Gestational Diabetes Mellitus is mounting , the consequences of   
8 
 
the diagnosis of Gestational Diabetes Mellitus for mother and child have become 
almost equal to, if not so important, than atleast its predictive value. 
 
2. CARBOHYDRATE METABOLISM DURING PREGNANCY: 
Glucose is the central component in energy metabolism. It is the preferred 
energy source for almost all cells. It comes from three sources. Ingested food, 
glycogenolysis, stored mostly in the liver and synthesis from the smaller molecules in 
the liver (gluconeogenesis). Almost all aspects of glucose metabolism and energy 
haemostasis are controlled by insulin and glucogan. Insulin is released from 
pancreatic beta cells into the portal circulation. Thus it reaches liver in very high 
concentration, but is much more dilute when it reaches peripheral target tissues 
including muscle and fat cells. Before it even leaves the pancreas, insulin exerts an 
important action in suppressing pancreatic alpha cells glucogan production. In the 
liver it stimulates glycogen synthesis and suppresses hepatic glucose production by 
suppressing both glycogenolysis and gluconeogenesis. In periphery the majority of 
insulin stimulated glucose uptake is into muscle cells and to a much lesser extent into 
adipocytes. When muscle cells insulin antagonises protein catabolism, promotes 
nitrogen retention and protein synthesis and promotes both glycolysis resulting in 
energy production and glycogen synthesis. Different mechanisms control blood 
glucose level in fed and fasting state. The fasting blood glucose level is controlled by 
the rate of glucose production from the liver. Various postprandial blood glucose 
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level are controlled by the rate of dispose of glucose absorbed from the gut into the 
muscle cells.  
 
In the fasting state insulin levels fall, glucogan level rises, liver is quickly 
(over 12-24 hours) depending upon calorie demand depleted of glycogen. Low 
insulin level permits muscle protein catabolism releasing amino acids mainly alanin 
into circulation which are taken in the liver to be used as the substrate for 
gluconeogensis. That glucose is then sent of into the circulation to meet total body 
energy needs. As continued, muscle catabolism to meet daily energy needs would 
ultimately be maladaptive. Other mechanisms served to maintain glucose levels in 
more prolonged fasting state. 4 key counterregulatory hormones – glucogan , cortisol 
, epinephrine , growth hormone. Mobilise fatty acid from triglycerides stored in 
adipocytes. Fatty acids are transported to the liver where they are converted to ketone 
bodies (mainly acetoacetate and beta hyroxy butyrate) are exported to be used by 
most tissues including brain to meet total body energy requirement within the liver 
fatty acid oxidation fuels hepatic gluconeogenesis.  
 
 Pregnancy is associated with   pancreatic beta cell hyperplasia and increased 
serum insulin levels in both fasting and fed state. Fasting sugar levels are usually 10 
to 15% lesser than the non pregnant levels while postprandial levels are slightly 
higher.  Early pregnancy is associate with improved insulin sensitivity, but as 
pregnancy progresses increased insulin resistance.  Insulin resitance is due to effect 
10 
 
of increased levels of several hormones. Cortisol, growth hormone, progesterone, 
estrogen and human chorionic somatotrophin (human placental lactogen). Newer 
evidence has the focus on role of various new mediators such as leptin ,TNF alpha 
and resitin for insulin resistance. kirwan and co-workers reported tnf alpha‘s 
coorelation with the insulin sensitivity changes from preconception time till last 
trimester. When a combination various placental hormones are taken into account 
multi various step wise analysis revealed that tumor necrosis factor alpha was the 
most strongest independant predictor of insulin sensitivity during pregnancy, which 
accounts for almost half of variance in the reduced insulin sensitivity during 
conception. Pregnancy is charecterised by reduced inflammatory condition due to 
increase in activation of circulating leucocytes. During fasting, a pregnant women 
accomplishes to switch from the use of hepatic glycogen for daily energy needs to 
lipolysis and ketone body production quickly and without going to intermediate stage 
of protein catabolism and amino acid used for gluconeogenesis described above. This 
rapid transistion from fed physiology to starvation physiology is termed as 
accelerated starvation of pregnancy. Glucose is transported across the placenta down 
a concentration gradient by facilitated diffusion in a non energy requiring process. 
Fetal glucose level are generally approximately 80% of maternal levels. Amino acids 
transportation across placenta happens actively against the gradient in a energy 
requiring process that results in fetal level of amino acids that are as much as 140 % 
of maternal serum levels. 
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3.PHYSIOLOGY/PATHOPHYSIOLOGY  
Genetics and Obesity appears to influence the insulin resistance during 
conception (Di Cianni et al, 2003). Inflammation and elevated serum ferritin levels in 
early pregnancy have also been cited as possible reasons for development of insulin 
resistance in GDM (Chen, Scholl & Stein, 2006; Wolf, Sauk, Shah, Jimenez-Kimble, 
Ecker & Thadhani,2003).  
 
Pregnancy usually is charecterised by hyperinsulinemia and increased insulin 
resistance. Insulin resistance and inadequate beta cell response with GDM are well 
understood now. 
 
The rates of diagnosis of GDM vary with the population studied and the 
methodology which are used for screening. Increased incidence of Gestational 
Diabetes Mellitus  also has a correlation with increased chance of Type 2 DM in 
general population is documented clearly in a lot of literature (Dabelea et al, 
2004;Vidaeff et al, 2002; Langer et al, 2003; Ana, van dr Ploeg, Cheng, Huxley & 
Bawman,2008). 
 
HAPO Study Research Group, 2002; The higher incidence of GDM in 
particular ethnic groups is clearly evident in certain literatures (Kings, 1997; Centre 
for Epidemiology & Research, NSW Health Department  2005; Dabelea et al, 2005). 
In the Dabela study, mentioned above, the last 3 groups of women, (African 
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American, Hispanic, & mostly  Asian women) were at high risk of developing 
Gestational Diabetes Mellitus. The women groups in high risk ethnic groups 
increased from 28% of all pregnancies in 1994 to 33% in 2003.  
 
Normal glucose tolerance 
There is a prominent alteration in the maternal metabolism during the 
pregnancy which provides for adequate maternal nutritional stores in early gestation 
in order to meet the increased maternal and fetal demands of late gestation and 
lactation. Although we commonly think of diabetes mellitus as a pure disorder which 
is exclusively related to maternal glucose metabolism, infact diabetes mellitus affects 
almost all aspects of the nutrient metabolism. 
 
Glucose metabolism:  
Normal pregnancy is characterised by a diabetogenic state, because of  
progressive increase in the postprandial blood glucose levels and an increased insulin 
response in later gestational period. Early gestation can be viewed as an anabolic 
state because of the increase in maternal fat reserves and the decrease in free fatty 
acids concentration. The mechanism for the reduction in the insulin requirement in 
earlier gestation is due to increase in the insulin sensitivity, decrease in the substrate 
availability which is secondary to factors such as nausea, the foetus acting as a 
glucose sink and enhanced maternal insulin secretion. The exact mechanism is not 
known. The Longitudinal studies which are done in women with normal glucose 
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tolerance has shown a significant amount of alterations in all aspects of blood glucose 
metabolism as early as end of the first trimester
6
.  
 
Although there is a progressive decrease in the fasting blood glucose with 
advancing gestation, the decrease in blood glucose is mostly a result of the higher 
plasma volume in the early gestation and an increase in feto-placental glucose use in 
the late gestation. The increase in the fasting maternal hepatic glucose production 
occurred, despite a significant increase in the fasting insulin concentration, thereby 
indicating a decrease in the maternal hepatic glucose sensitivity in women with 
normal glucose tolerance. In addition in these obese women, there was a reduced 
ability for the infused insulin for suppressing production of hepatic glucose in the 
later gestation compared with the pre natal and early pregnancy measurements, there 
by indicating a further decrease in the hepatic insulin sensitivity in these obese 
women. 
 
During first and early part of mid-trimester, there is increased sensitivity and 
diabetic patients have the tendency towards hypoglycaemia. This enhanced insulin 
sensitivity probably due to high level of estrogen. The opposite occurs in third 
trimester, there is increased insulin resistance due to antagonistic effect of human 
placental lactogen cortisol, prolactin. progesterone, estrogen. However newer recent 
evidence has shown that a lot of new mediators of insulin resistance such as resistin, 
leptin, tumor necrosis factor alpha. 
14 
 
Pregnancy is characterised by a chronic low grade inflammation because of 
the increase in the activity of higher circulating blood leucocytes. The inflammation 
of pregnancy is further accelerated by mothers pre pregnancy obesity. This increased 
inflammation is particularly observed in obese women who has been related to 
increase in macrophagic infiltration in both maternal wide adipose tissue and 
placenta. The increase is evidenced with inflammation and is associated with an 
increase in CRP and interlukin.  
 
These 2 factors exacerbate the increase insulin resistance which was 
previously seen in these obese women who are with normal glucose levels. Some of 
these inflammatory factors relate to the substrate availability for the development of  
fetus and finally resulting in macrosomia. Placental glucose transport is a non energy 
mechanism and it takes place through the facilitated diffusion. Glucose transport is 
dependent on GLUT glucose transporter family. The glucose transporter  in placenta 
is GLUT1 which is located in syncytiotrophoblast .  The fetal glucose levels are thus 
reflection of maternal levels, being 10 mg/dl lower when comparing to the mother. 
Maternal insulin does not cross the placenta and the fetus produces its own insulin 
from the late first trimester. In diabetic mother, the fetal blood glucose does not 
increase to the same extent as maternal. Nature seems to have created a protective 
mechanism that cuts off the system of facilitated diffusion at maternal plasma 
glucose levels more than 200 mg/dl. However the fetal response becomes more brisk 
which is secreted in response to glucose and amino acids as if the fetus recognises the 
15 
 
need to maintain its own haemostasis. Pederson proposed ―hyperglycaemic - 
hyperinsulinism‖ theory. 
 
4.EFFECTS OF DIABETES ON PREGNANCY 
Most of the group of women with gestational diabetes mellitus do not have 
any major signs and symptoms initially. Carbohydrate intolerance during pregnancy 
have major negative effects on the mother as well as the fetus. 
The major effects of diabetes mellitus on pregnancy are 
16 
 
1. Preeclampsia – hypertensive disorders in pregnancy. The incidence of 
preeclampsia is approximately 15% and it is associated with poor glycemic 
control and end-organ damage
4
.  
2. Infections are more prone during pregnancy with DM. The common infections 
that can occur are pyelonephritis,  urinary tract infections, bacteruria, 
chorioamnionitis, postpartum endometritis, wound infections, serous discharge 
from wound 
3. Polyhydramnios (25 -50%). The common clinical scenario are large baby, 
large placenta , increased liquor levels, fetal polyuria, increased chance of 
congenital anomalies occurring along with polyhydramnios 
4. Chance of spontaneous abortions 
5. Increased chance of still birth  
6. Malpresentation 
7. Ketoacidosis , chance of diabetic coma 
8. Increased need of insulin dosage during pregnancy 
9. More chance of instrument deliveries 
10. Shoulder dystocia 
11. Post partum haemorrhage  
12. Chance of LSCS for macrosomia 
13. Pelvic floor trauma 
14. Post partum infections are more common 
17 
 
15. Development of organ dysfunction – retinopathy , nephropathy, diabeteic 
neuropathy , diabetic cardiomyopathy 
16. Preterm Labour: The risk of spontaneous preterm births  as 28% higher in 
women who were screen positive but had normal GTT, and 70% higher in 
women who were classified as gestational diabetes by the Carpenter and 
Coustan criteria. 
 
5.EFFECTS OF DIABETES ON FETUS: 
1.Congenital abnormalities: 
          Mainly associated with type 2 diabetes mellitus. Organogenesis occurs at 5-8
th
 
week of gestational age. Congenital abnormalities are 3- 10 times more common  
with uncontrolled diabetes. Minor congenital abnormalities are 9.5% increased and 
major congenital abnormalities are 16.5% common. When Hba1c is more than 9.5 
then chances of anomalies are 22% commoner. Commonest malformation are CVS- 
ASD, VSD, TGA, hypoplastic left heart , TOF, Truncus arteriosis , situs inversus 
CNS- spina bifida, anencephaly, encephalocele, meningomyelocele, hydrocephalus, 
holoproscencephaly, GUT- renal agenesis , polycystic kidneys , ureteric duplication, 
GIT- anal & rectal atresia,  Skeletal- caudal regression syndrome and sacral agenesis 
2. Hypoglycaemia: Hypogycemia occurs due to fetal hyperinsulinemia. Blood sugar 
in normal babies is 60-80 mg/dl. Hypoglycaemic babies are < 35-40 mg/dl. Babies 
are usually lethargic, failure to feed, seizures 
18 
 
3. Hyperviscosity syndrome: Venous haemotocrit is usually higher than 65%. 
Fetal hyperglycemia causes increased tissue hypoxia, increased erythropoietin, 
increased viscosity, poor circulation and causes increased vascular sludging. Which 
leads to ischaemia and microthrombi and finally ends up in infarction in kidneys 
and brain and adrenals 
4.Hypocalcemia: Calcium levels are usually < 7 mg/dl.  In first few days calcium 
levels are low in babies born to diabetic pregnancies, more in preterm and 
asphyxiated babies and because of neonatal hypoparathyroidism.  
5.Hypomagnesemia: Hypomagnesemia occurs mainly due to increased renal losses 
in poorly controlled case. 
6.Macrosomia: Increased weight occurs due to excess glycogen stores in the body 
mainly in the subcutaneous tissues 
7.Hyperbilirubenemia: From day twoin (20-25% of cases) hyperbilirubinemia 
occurs due to prematurity, immature hepatic bilirubin conjugation, breakdown of rbc 
due to neonatal polycythemia. Birth trauma also causes hyperbilirubinemia due to 
bruising and hematoma formation  
8.Apnea and bradycardia: Respiratory distress occurs due to reduced surfactant 
levels. Usually cortisol from the placenta acts through the  pulmonary fibroblast, for 
the synthesis of fibroblast pneumocyte factor, which acts on type 2 pneumocyte for 
synthesis of phospholipid. Insulin blocks the cortisol action at level of fibroblast by 
decreasing the formation of fibroblast pneumocyte factor. LSCS in such mothers also 
has increased risk. Tests for fetal lung maturity must be done wherever necessary. 
19 
 
9.Fetal death : Still birth observed most often after 36
th
 week of gestation. 
Hyperinsulinemia, hyperglycemia, pre eclampsia, diabetic ketoacidosis, maternal 
vasculopathy leads to chronic hypoxia. Extramedullary hematopoisis has been 
observed in still born IDMs, supports chronic intrauterine hypoxia as a cause for intra 
uterine death. 
  
Long-term impact of Gestational Diabetes Mellitus on maternal health 
Antenatal mother with Gestational Diabetes Mellitus are usually at a higher 
risk of the development of Type II Diabetes mellitus, post conception. Obesity and 
other factors which leads to the insulin resistance appears to further higher the  risk of  
Type II DM after GDM, Increased risk of obesity type II diabetes in children and 
adults who are exposed to hyperglycaemia in utero
7
. Approximately 5% - 10% of 
women with Gestational Diabetes Mellitus periodically may develop Type I 
diabetes
8
. Mothers with GDM have a higher lifetime risk of developing diabetes 
mellitus, more than 30% versus 10% in the normal controls at sixteen yrs after the 
index pregnancy 
9
. 
 
The increased demand of insulin which occurs during pregnancy, overweight , 
obesity and excess weight increase post-delivery may also be associated with an 
higher risk of development of future DM, mostly Type II Diabetes mellitus
10,11 
Other predictors of GDM are positive family history of Type II DM, further 
pregnancies 
12
, and a probable sluggish response for the oral sugar load. 
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It is proper to target the women who are diagnosed with Gestational Diabetes 
Mellitus by means of health education to reduce CVS risk factors, as morbidity & 
mortality from premature cardiac disease markedly increases in diabetic women
13
.
 
The main importance of proper weight maintaining and proper exercises must 
be stressed very importantly, both for CVS protection and also for the delaying the 
onset of Impaired Glucose Tolerance and Type II diabetes 
14,15
. 
 
6.EFFECTS OF PREGNANCY ON DIABETES MELLITUS 
The patients with diabetes have a tendency to go for metabolic instability and 
may need more frequent blood sugar level monitoring. Continues adjustment and 
titration of insulin levels are needed. Life style modification is needed. Pregnancy 
with diabetes associated with organ dysfunction will accelerate organ damage easily 
and in general may need intensive measures and therapeutic ways to compensate 
from reaching the end organ damage. 
 
Diabetics with End-Organ Damage 
(a) Diabetic nephropathy 
The features which mostly signifies diabetic nephropathy in diabetic mothers 
are proteinuria and increased Blood pressure in the first or second trimester of 
pregnancy. Particularly around 20-24 weeks most of these patients have increased 
proteinuria, blood pressure and serum creatinine increase. Edema is almost always 
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present. Pregnancy has an adverse effect on advanced diabetic nephropathy and 
patient withserum creatinine more than 1.5 mg/dl or proteinuria more than 3g/24 
hours may progress to end stage renal disease.  Fetal growth restriction and 
prematurity is the commonest sequel. These women are at high risk of developing 
superimposed preeclampsia, which affects 50% of pregnant diabetics with renal 
disease. The incidence of preterm delivery in these patients is approximately 40-45%. 
Fetal growth restriction occurs in approximately 20% of renal disease. 
 
(b) Diabetic retinopathy 
Diabetic retinopathy occurs in approximately 40% of pregnant mother with 
insulin-dependent diabetics. 75% of these cases, have ―background retinopathy.‖ 
20% of these patients have marked neovascularization along the retinal surface, and 
this is named ―proliferative retinopathy.‖ Cotton wool infarcts and marked 
neovascularisation are the common ones seen. The important group to identify is the 
latter ones because the new vessels are fragile and may bleed profusely with 
intraocular pressure increase that occurs during labor, which leads to sudden vision 
impairment. Therefore, labor is contraindicated in these kind of patients because 
Valsalva efforts may have an increase in the intraocular pressure which causes vitreal 
hemorrhage and sudden retinal detachment. Usually Caesarian section is commonly 
preffered in such kind of patients. 
 
(c) Diabetic neuropathy 
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Gastroparesis, increased nausea and vomiting occurs in them continuously and 
they frequently develop starvation ketosis. Treatment is by intermittent gastric 
intubation or from the administration of metoclopramide or erythromycin. 
Loss of sensation of any particular area commonly in the foot. 
 
(d) Coronary artery disease: 
Coronary artery disease occurs in long standing diabetic mothers and 
particularly they develop hypertension, nephropathy , increased myocardial stress , 
increased adrenaline. Cardiomyopathy also occurs in these patients who have a pre 
existing diabetes mellitus. Prognosis is poor in such kind of patients. Management 
with cardiac-obstetric care unit. Myocardial infarction also occurs in such kind of 
patients. 
 
(e) Metabolic Syndrome 
The metabolic syndrome occurs in the patients who is already having diabetes 
for a long term The metabolic syndrome is a consolidation of the traditional 
cardiological and metabolic risk factors that includes central obesity, dyslipidemia 
and hypertension, hypertriglyceridemia, and a reduced (HDL) high-density 
lipoprotein  and cholesterol levels. In the latest years, the clinical utility and the 
diagnostic criteria and the etiology have been subject to continuous debate and 
controversy. While this debate continues for a long time, it further remains 
inconvertible for those who are identified with the metabolic syndrome who are at 
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high risk for the future development of type 2 diabetes (T2DM) and the 
cardiovascular disease (CVD). In addition, an expanding body of the evidence has 
been linked to the metabolic syndrome with several emerging non-traditional risk 
factors, including markers of hepatic fat, chronic inflammation (CRP), and adipocyte 
dysregulation (such as low circulating levels of adiponectin). Interestingly, many of 
these features of the metabolic syndrome are also common to gestational diabetes 
mellitus (GDM). Gestational Diabetes Mellitus has also been subjected for long 
standing discussion and debate for a long time in its history and it also identifies the 
women who are at increased risk of developing Type II Diabetes Mellitus and Cardio 
Vascular Disease in the future. The metabolic syndrome is an age dependent factor 
and in United States of America it is reported in 8% of individuals between 21 and 29 
years of age and in 43% of those aged 61-69 yrs
16. 
 
(f) Diabetic ketoacidosis 
Diabteic Ketoacidosis is a very serious emergency where usually patients have 
increased sugar levels of > 250 mg/dl , ketonemia, ketonuria more than 3+ and 
bicarbonate levels less than 15 meq/l and pH <7.3 and reduced potassium levels. 
The common symptoms are dehydration, tachycardia , tachypnoea , hypotension, 
confusion , coma.  Complete blood count , urea and serum electrolytes are seen. Iv 
fluids mainly normal saline must be given to correct the fluid defecit. Sliding scale of 
insulin correction is done. Potassium correction is also commonly done.  In DKA the 
cells start to use fatty acids as a source of energy (lipolysis) with production of 
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ketoacids that consume the body buffers, resulting in a high anion gap and metabolic 
acidosis. If uncorrected, this may lead to maternal and fetal death. This emergency 
requires early diagnosis and aggressive treatment with identification and elimination 
of the precipitating event. 
 
7. TERMINOLOGY AND CLASSIFICATION: 
The traditional definition of gestational diabetes mellitus (GDM)used by 
American college of obstetrics & Gynaecology (ACOG)
17
 is any degree of glucose 
intolerance that either or first diagnosed in pregnancy. This definition does the 
possibility that   the   diabetes   may   have   existed   but   been unrecognised prior 
to pregnancy
18
. 
 
In 2010, the International Association of Diabetes and Pregnancy Study Group 
(IADPSG), An international collaborative group, recommended new terminology for 
GDM based on HAPO study. 
 
Under the new IADPSG terminology, Diabetes that  is first  recognised  in 
pregnancy can be  classified as either ‗overt‘ or gestational‘. This recognises that an 
increasing number of women have unrecognised type 2 diabetes at the time of 
conception, which is associated with a higher risk of pregnancy outcomes including 
congenital anomalies, as well as diabetic complications
19 
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Overt diabetes is present if any of the following values are  found at the first 
antenatal visit of pregnancy: 
Fasting plasma glucose  ≥ 126 mg/dl (7.0 mmol/l) 
HbA1c    ≥ 6.5%  (on a standardized assay) 
Random  plasma  glucose ≥ 200 mg/dl (11.1  mmol/l) 
plus confirmation with a fasting plasma glucose or HbA1c value suggestive of overt 
diabetes mellites. 
 
National Diabetes Data GROUP: etiologic classification of diabetes: 
Type I diabetes mellitus (beta-cell destruction usually leading to absolute insulin 
deficiency) Immune-mediated Idiopathic. 
 
Type  II  diabetes  mellitus  (may range from  predominantly insulin resistance  with 
relative  insulin  deficiency to  a predominantly  insulin secretory defect with insulin 
resistance) 
Other specific types of diabetes beta-cell function  
Genetic defects 
Exocrine pancreatic disorders  
Endocrinopathies 
Drug – or chemical-induced Infections  
Genetic defects in insulin action 
Uncommon forms of immune-mediated diabetes  
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Other genetic syndromes associated with diabetes  
Type III Gestational diabetes mellitus 
American Diabetes Association. Report of the expert committee on the diagnosis 
and classification of diabetes mellitus. Diabetes Care 2000; 23 (Suppl 1): S4 
 
White’s classification of diabetes during pregnancy: 
Gestational diabetes 
Class A1 
 
Class A2 
Discovered during pregnancy, glycemia may or may not 
be maintained by diet alone and insulin may be required 
FBS<105mg/dl, 2hrs PPBS<120MG/DL-Therapy with 
diet 
FBS>105mg/dl, 2hrs PPBS>120MG/DL-Therapy with 
insulin/OHA 
Class B Onset age More than20 yrs , duration less than 10 years 
Class C Onset of age 10-19 yrs, duration 10-19 yrs 
Class D 
Onset age less than 10 yrs, duration more than 20 yrs, 
benign retinopathy 
Class R Proliferative retinopathy or vitreous haemorrhage 
Class F Nephropathy with proteinuria over 0.5gm/day 
Class RF Criteria for both  R and F classes coexist 
Class H Arteriosclerotic heart disease clinically evident 
Class T Prior renal Transplantation done 
Hare J.W  White P. GDM and the White classification. Diabetes Care 1980; 3: 394 
But, White‘s classification is not ideal and should not  be  used  alone because  
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the  number of  groups  is  large  and because patients in the same group may have 
completely different prognosis. The current tendency is to classify the patients by 
type and then by White`s class. 
Major  recent  research  in  gestational  diabetes has focused  on  redefining 
glucose  thresholds  for  diagnosis and treatment targets, as well as more flexible 
approaches to treatment based on foetal parameters and expanding the treatment 
options available. 
8. SCREENING METHODS 
There are several conditions that should be fulfilled in order to adopt a 
generalized screening method during pregnancy: 
The condition to be screened for should have a significant impact on maternal 
and fetal health.The  screening  method  should  have  high  sensitivity  and  
specificity.An  effective  method  should  be  available to  treat the condition  and  
reduce its  impact  on  the outcome of pregnancy. 
The US Preventive Services Task Force
20
 and the American College of 
Obstetricians and Gynecologists (ACOG) recommend selective screening of high-
risk women. However, most obstetrical practices find it impractical to select patients 
at high risk, and generalized screening is predominant. Some communities may have 
a prevalence of gestation diabetes as high as 14% and in this case the number of false 
positive will be small even if the lower threshold is adopted for screening. 
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Risk assessment and timing of screening for gestational diabetes 
Low risk 
All of the following: 
 Member of an ethnic group with a 
low prevalence of GDM 
 Not a  known diabetic in first-
degree relatives 
 Age Less than 25 years 
 Weight normal  during 
prepregnancy 
 normal  birth weight 
 No known history of abnormal 
sugar metabolism 
 
Blood glucose screening not 
routinely required 
Average risk 
One or more of the following: 
 Member of ethnic group with a 
high prevalence of Gestational 
Diabetes 
 Diabetes in1st-degree relative 
 Age more than 25 years 
 Overweight before pregnancy 
 Weight high at birth 
 
Blood glucose testing at 24-28 
weeks (one-or two- step procedure) 
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High risk 
 Marked obesity 
 Strong family history of type II 
Diabetes 
 Previous history of Gest Diabetes, 
impaired sugar Metabolism or 
glucosuria 
Perform glucose testing as soon as 
feasible 
 
According to the 1997 recommendations, screening and diagnosis were 
undertaken as a ‗two-step‘ approach.  If the screening test, the glucose challenge test, is 
positive, that is the blood glucose level ismore than or equal to 140 mg/dl, the 
diagnostic test, 3-hour 100 g GTT is recommended. Using the cut-off a 140 mg/dl, 
about 80% of gestational diabetics can be detected and 15% patient will need to 
undergo GTT. 
 
Targeted or Universal Screening: 
The American Diabetes Association (ADA) recommends that women  are low  risk  
and  need not  undergo  routine  screening if they they will meet  all  of  these 
following criteria: normal weight, age  <  25years,  ,  not  of  a  high-risk  ethnic  group, 
there is no  family  history of diabetes, there is  no  personal  history  of abnormal  
glucose metabolism or poor obstetric outcome.  
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It also recommends early screening for GDM (in the first trimester) if there is a 
history of severe obesity, a family history of type  2  diabetes mellites, , polycystic 
ovarian syndrome, previous GDM or large for gestational age (LGA) infant, 
glycosuria, or  with  re-testing at  24-28  weeks gestation  if  the initial screening is 
negative. However, a study that attempted to apply these criteria found that only 10% 
of women actually met all of these criteria and thus avoided the need for screening. 
Therefore,   in   the   interest   of simplicity, many other 
(18,21) 
organizations recommend 
universal screening. 
An  increased  risk  of  various  maternal  and  fetal adverse outcomes have 
now been well – documented, although the benefits of treatment had remained 
controversial until recently, fuelling the debate on universal versus selective screening 
 
SCREENING OF GESTATIONAL DIABETES MELLITUS 
 One-step approach: diagnostic OGTT without glucose screening test. This one-
step approach may be affordable cost for  higher-risk patients or population 
(e.g., some native-American groups).  
 Two-step approach: initial screening is by measuring 
o Glucose challenge test 
o Screening for gestational diabetes is performed by orally 
administering 50 g of glucose and measuring the venous plasma 
glucose 1 hour later. It is not necessary to follow a special diet before 
the test and it is not necessary to be in a fasting state. 
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Plasma  glucose  values  should  not  be  substituted  with  capillary reflectance  
meter  glucose  values because papillary blood shows higher blood sugar values. The 
sensitivity of the test is related to the threshold used for diagnosis and with the 
prevalence of the condition in the population. When 130 mg/dl is used as the 
threshold, the test will have a sensitivity of 90%, which decreases to 80% when the 
threshold is 140 mg/dl. If glucose challenge test value is high patients were subjected 
to OGTT. 
ACOG: 
The two-step approach starts with a 50g glucose challenge test (GCT) as a 
screening test, followed by a 100 g oral glucose tolerance test if the GCT is positive. 
Diagnostic criteria for the 100-g OGTT are derived from the original work of 
O‘Sullivan and Mahan, modified by Carpenter and Coustan. 
 Table : Diagnosis of GDM with 100-g oral glucose load 
 
CARPENTER AND 
COUSTAN(MG/DL) NDDG(MG/DL) 
Fasting 95 105 
1 – hr 180 190 
2 – hr 155 165 
3 – hr 140 145 
 
2 or more venous plasma concentration must be there or exceeded for a proper 
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positive diagnosis. This test must be done in early morning after overnight fasting of 8 
hours to 14 hours and with after at least 3 days of unrestricted diet (>150 gram  
carbohydrates/day) and maximum physical activity. The subject must remain seated 
during that time and must not smoke during the test. 
Various  national & international medical organizations, along with the  expert 
panels and working group, have issued specific guidelines with recommendations of 
proper  screening and diagnosing Gestational Diabetes Mellitus. In 2001, the ACOG 
recommended ,for almost  all pregnant women, must always be screened for 
Gestational Diabetes Mellitus— whether by patient history, clinical risk factors, or 
with a 50-gm, 1-hr loading test at 24 to 28 weeks of gestational age to determine 
blood sugar  levels––and suggested relying on result of the 100-g, 3-hr oral glucose 
tolerance test for the  diagnosis 
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IADPSG, 2010 recommends the one-step diagnostic OGTT between 24 and 28  
weeks gestation,  overall they recommend a 2-phase stratergy aimed at detecting both 
overt diabetes in early pregnancy, as well as true gestational diabetes at a later 
gestation  
Strategies for proper detection & diagnosis of hyperglycemic disorders during 
pregnancy  (IADPSG II phase strategy ) 
First prenatal visit  
Measuring Fasting blood Glucose, glycosylated haemoglobin HbA1C, or 
random glucose from plasma  on all or from the high-risk women alone 
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If the results are indicating overt diabetes - Proper treatment and follow-up as 
we do for pre-existing diabetes mellitus 
If results are not diagnostic of overt diabetes and fasting  glucose levels  ≥5.1 
mmol/l (92 mg/dl) but  less than <7.0 mmol/l (126 mg/dl), diagnose as Gestational 
Diabetes and fasting glucose levels <5.1 mmol/l (92 mg/dl), test for Gestational 
Diabetes Mellitus  from 24 to 28 weeks  gestation with a 75-gm Oral Glucose 
Tolerance Test 
24–28 weeks  gestation age : diagnosis of GDM 
2-hour 75-gram OGTT: perform after proper overnight fasting on all the 
women who have not been  previously found to have overt diabetes or GDM during 
testing earlier in this pregnancy 
Overt diabetes:  if the fasting plasma glucose levels ≥7.0 mmol/l (126 mg/dl) 
Gestational Diabetes Mellitus: if one or more values equals or exceeds 
IADPSG threshold levels 
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Normal: if all the values on Oral Glucose Tolerance Test less than thresholds 
 
 
 
 
the  new  
recommendations,  all  women not known  to  have  diabetes earlier  should  undergo  
a  75-g  OGTT at  24-28  weeks  of  gestation.  A fasting blood  sample  is drawn,  
following which the woman is instructed to drink a solution of 75gm glucose 
dissolved in a glass of about 300 ml of water over a period of 5 – 10 minutes. Some 
lemon juice can be added to the glucose water to prevent nausea and vomiting that so 
often follows the rapid ingestion of so large a quantity of glucose on an empty 
stomach.  Thereafter, plasma glucose levels are estimated after 1 hour and 2 hours, 
which means that total three blood samples are taken.  Gestational diabetes is 
diagnosed if any one of the three values is met or exceeded. 
                   
          WHO The  initial  criteria  used  for  diagnosis  of  GDM  were established  in  
the  1960‘s23,and  have  undergone  only  slight modifications  since  then. 
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The American Diabetes Association (ADA) and the World Health Organisation 
diagnostic criteria for the Gestational Diabetes Mellitus were analysed against the  
pregnancy outcomes. A cohort study was done and a lot of Brazilian adult women 
were enrolled and they were attending  prenatal checkups. All the women were 
requested to undergo a standardized 2-hour 75-gm Oral Glucose Tolerance Test 
between their planned 24
th
 and 28
th
 week of antenatal period and were then followed 
up until birth. 
Gestational Diabetes Mellitus based on a 2-hour 75-gm Oral Glucose Tolerance 
Test as defined by either World Health Organisation or American Diabetes 
Association criteria and was able to predict the adverse pregnancy outcomes
24
.The 
recommendations of World Health Organisation and American Diabetes Association 
WHO, ADA recommends one step criteria 
Criteria followed by WHO and ADA for a positive 75 g OGTT in pregnancy 
are described below: 
Criteria for a Positive 75 g OGTT in Pregnancy 
 Fasting plasma 
glucose 
1 Hr Plasma 
glucose 
2 Hr Plasma 
glucose 
World Health 
Organisation 
≥ 126 mg/dl 
≥ 6.9 mmol/l 
 ≥ 140 mg/dl 
≥ 7.8 mmol/l 
American Diabetes 
Association 
≥ 92 mg/dl 
≥ 5.1 mmol/l 
≥ 180 mg/dl 
≥ 10.0 mmol/l 
≥ 153 mg/dl 
≥ 8.5 mmol/l 
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                In India Diabetes In Pregnancy Study Group India has recommended  
universal screening single test screening as well as diagnosis. Two hours 75grams oral 
glucose venous blood is collected. 
 
Values interpreted are as follows- 
 121-130-impaired glucose tolerance 
 <140mg/dl-nornal,  
 >=140-199mg/dl-gestational diabetes mellitus 
 >=200mg/dl-overt diabetes 
Screening is done at 24-28 weeks, at at any time of the day, irrespective of the time of 
last meal. 
In high risk patients it is done at first antenatal visit and if normal it is repeated at 24-
28 weeks and 32-34 weeks. 
Advantages of DIPSI 
- Fasting status not required 
- Does not alter her routine activities 
- Both screening and diagnostic 
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9. LITERATURE REVIEW 
RISKS OF GESTATIONAL DIABETES 
Gestational Diabetes mellitus as defined by the WHO diagnostic criteria is well 
documented to be associated with multiple complications for both the mother and 
foetus  
RISKS OF MILDER HYPERGLYCAEMIA 
However until relatively recently, it was not clear whether milder degrees of glucose 
intollerence, including at levels below the traditional thresholds for a diagnosis of 
GDM ,were a significant risk for adverse pregnancy outcomes .two major recent 
studies addressing this issue are the HAPO study and another secondary analysis of 
the randomised controlled study by London et al in 2011. 
 
HAPO STUDY: HYPERGLYCAEMIA AND ADVERSE PREGNANCY 
OUTCOMES 
In this large propective observational study of around 25,000 women in nine 
countries, participants underwent a 75g 2- hour OGTT between 24 and 32 weeks 
gestation .8 patients and caregivers remained blinded to  results providing glucose 
level did not reach predefined thresholds (fasting glucose >105mg/dl (5.8mmol/l)and 
2-hr glucose levels >200mg/dl(11.1mmol/l).thus the group studied only women with 
glucose values of previously uncertain significance.this blinding excluded the 
possibility of caregiver bias, whereby an expectation of adverse outcomes might 
influence the rates of intervention. 
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The results of fasting levels, 1-hour levels and 2-hour levels glucose 
measurements were each stratified into 7 risk categories. The main outcomes were 
weight at birth. 90
th
 percentile for gestational age, primary c section , properly  
diagnosed neonatal hypoglycaemia and the cord-blood  serum C peptide maternal 
glucose categories, although this was not as marked for neonatal hypoglycaemia and 
primary caesarean section. Comparing the lowest versus the highest glucose category 
for fasting plasma glucose, the prevalence of birth weight >90
th
 percentile 
was5.3vs.26.3%, for primary caesarean section 13.3 vs.27.9%for clinical neonatal 
hypoglycaemia 2.1vs 4.6% and for C-Piptide. 90
th
 percentile was 3.7 vs 32.4%. 
Similar results were noted with the 1-hour and 2-hour glucose measures, and no one 
out of the three time –points tested demonstrated superiority when it came to 
predicting the primary outcomes .this equated to an 8-11% increase in primary 
caesarean section for each bio standard deviation increase in glucose level. 
 
In addition, pre-eclampsia increased by 21% and the shoulder dystocia or birth 
Injury by 18% for each standard deviation increase in fasting glucose levels (with 
similar findings for the 1-hr and 2-hr levels). However premature delivery, neonatal 
ICU admission and increased bilirubin levels were associated with the 1-hr and 2-hr 
levels but not the fasting plasma glucose. The study was not powered to detect an 
increase in perinatal death, and no such difference was found.  
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Perhaps most importantly, there was no demonstrable threshold effect for any 
of these increased risks, and risks were certainly increased below the level of 
traditional cut-offs for the diagnosis of GDM. 
 
In a secondary analysis, the HAPO study collaborative group looked at associations of 
obesity and gestational diabetes with pregnancy outcomes. Obesity alone (without 
GDM) was associated with a 1.73 times increased odds ratio of birthweight >90
th
 
percentile compared to non-GDM and non-obese women. The presence of GDM as 
well as obesity increased this risk to 3.62. Higher maternal body mass index (BMI) 
was associated with a continuous increase in risk. 
 
MATERNAL- FETAL MEDICINE UNITS (MFMU) NETWORK CLINICAL 
TRIAL FOR TREATMENT OF MILD GDM 
This trial also concluded that the existing diagnostic thresholds for GDM 
needed to be re-evaluated due to the finding of a continuous relationship between 
increasing maternal glucose level and adverse perinatal outcomes. This secondary 
analysis of over 1800 patients from a treatment trial for mild GDM categorised 
patients into those with a normal glucose-challenge test (GCT), abnormal GCT but 
normal oral glucose tolerance test (OGTT, using the fasting cut-off from the HAPO 
study but traditional cut-offs for the other values), abnormal GCT and one 
abnormality on OGTT, and gestational diabetes (two or more abnormalities on 
OGTT). 
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Across these four categories, there was a significant increase from patients with 
a normal GCT to these with GDM in perinatal outcome (perinatal mortality 
hypoglycemia, increased bilirubin levels, higher cord blood c-peptide and birth 
trauma, around 26% vs. 37%), large for the gestational  age babies (6.7% vs. 14.5%), 
elevated cord C-peptide (around 12% vs. 23%), shoulder dystocia (approximately  
0.8% vs. 4%) and gestational hypertensive disorders (around 7% vs. 14%). No trend 
was seen for neonatal hypoglycaemia or hyperbilirubinaemia considered as separate 
outcomes. 
 
In addition, a positive GCT was correlating with a significant rise in the 
composite outcome and LGA infants when compared to a normal screen, and 
untreated GDM, as compared to patients with a positive GCT but a negative OGTT, 
was associated with an increase in all the outcomes except the composite outcome. 
There was no remarkable change in any outcome when GDM was compared to a 
positive GCT followed by a single abnormal value on OGTT. 
 
Analysis for patients who had on OGTT showed a significant increasing trend  
across glucose categories for the  outcome, increased cord C-peptide level and LGA 
frequency for increasing hyperglycaemia in each of the fasting and three post-glucose 
levels. This was not seen across all glucose measurements for shoulder dystocia and 
hypertensive disorders, but it should be noted that patients with normal glucose 
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tolerance were not included in this analysis as they did not do OGTT. A fasting 
glucose level of 85-89 mg/dl was correlated with higher risk for elevated cord C-
peptide level and LGA infants, and 90-94 mg/dl for the composite outcome, both well 
below the traditional fasting glucose cut-off level for a diagnosis of GDM. 
 
Therefore, overall the MFMU study supported the findings of the HAPO study 
in finding a continuous relationship between maternal glucose levels and adverse 
outcomes. The finding of no significant outcome differences between women with one 
or more abnormal OGTT values also supported findings from HAPO, and calls into 
question the ―traditional ― requirement for two abnormal value on OGTT diagnose 
GDM.  
A Danish observational study of nearly 3000 women had similar findings, 
looking at outcomes of shoulder dystocia, caesarean section rate, spontaneous preterm 
delivery and macrosomia. 
In a study, which enrolled 1464 pregnant women who underwent IADPSG 
screening and DIPSI criteria screening. The objective of this study was to find out if 
DIPSI could diagnose GDM against the IADPSG. The prevalence of GDM with 
DIPSI was 13.4% (n=196) and IADPSG was 14.5% (n=214) and concluded that there 
was no statistical significance (P=0.21) between the 2 test and therby implied a close 
agreement between the 2 tests. 
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EVIDENCE OF THE BENEFIT OF DIAGNOSIS AND TREATMENT OF 
GESTATIONAL DIABETES 
Although the risks associated with gestational diabetes are now well-
described, up until recently it remained unclear whether treatment, especially with 
milder degrees of glucose intolerance, ameliorated these risks. However, recent 
studies have now proven that this is the case. 
The Australian carbohydrate intolerance study in pregnant women (ACHOIS) 
trial was designed to investigate if the treatment of Gestational Diabetic Mothers 
reduced the risk of perinatal complications. In this study, a diagnosis of GDM was 
made if the fasting glucose was <140 mg/dl (7.8 mmmol/l) and the two –hours 
glucose 140-198 mg/dl (7.8-11 mmol/l). Patients were randomly assigned to the 
intervention group (that is, they were told they had GDM and treated with dietary 
advice, glucose self-monitoring and insulin if required), or to the routine care group 
(who were told that they did not have GDM). To preserve blinding, up to 1 in 5 
women with normal OGTTs were also assigned to the routine care group. The actual 
results were provided to the women and their caregivers prior to discharge from 
hospital. 
Analysis of the results showed reduced serious perinatal outcomes (a 
composite of death, difficult shoulder delivery, bone fractures or nerve palsy) in the 
intervention group (1% versus. 4%). Admission to the neonatal nursery was increased 
at 71% in the intervention vs. 61% in the regula care group, as induction of labour 
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(38% vs. 28%), perhaps reflecting the awareness of the diagnosis by the patient‘s 
provider. Insulin therapy was prescribed for 20% in the intervention group compared 
to 3% in the routine care group. Other benefits in the intervention group included less 
weight gain (8.1 vs. 9.8kg), a reduced rate of pre-eclampsia (12% vs. 18%) and a 
lower risk of depression at 3 months postpartum (8% vs.17%). Infants born to the 
Diabetic mothers in the intervention group,  were born at an earlier gestational age  
and had lower mean birth weights, but  also had a reduced likelihood of being large 
for gestational age (13% in the intervention group vs. 22% in the routine care group). 
There were 5 perinatal deaths in the routine care group compared to none in 
the intervention group, but this result was not statistically significant with an adjusted 
p value of 0.07. There was also a non-significant difference in rates of shoulder 
dystocia between the two groups (1% in the intervention group vs. 3% in the routine 
care group, adjusted p=0.08).  
There was no remarkable difference between  two groups in terms of neonatal 
jaundice, neonatal   hypoglycaemia requiring intravenous therapy , caesarean section, 
or rates of antenatal hospital admission. 
In a study by Langer et al.
25
 gravidas who were not treated for gestational 
diabetes who were previously diagnosed after 37 weeks were matched with 1110 
women with properly treated gestational diabetes and 1110 women without gestational 
diabetes. A composite adverse outcome was 59% for untreated, 18% for properly 
treated, and 11% for non-diabetic subjects.  
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10. TREATMENT OPTIONS FOR GESTATIONAL DIABETES MELLITUS 
1. LIFESTYLE  INTERVENTIONS 
1a. NUTRITIONAL THERAPY 
The first step in the meal planning for GDM or other pregnant diabetics is 
Refer patients for nutritional counseling with registered dietitian familiar with 
pregnancy, then calculate the optimal total daily caloric intake. Calculation of the total 
daily caloric intake is based on the number of calories necessary to maintain 1 kg of 
body weight, which is 30 kcal for the average normal-weight women (80-120% ideal 
body weight), 35-40 kcal for women who are underweight (less than 80% ideal body 
weight), 25 kcal for overweight women (121-150% ideal body weight), and 12 kcal/kg 
for morbidly obese women (more than 150% ideal body weight).  
This number is multiplied by the body weight in kilograms to obtain the total 
number of calories that the patient should consume during a 24-hour period. Diet 
should contain 40-50% should contain complex carbohydrate, The carbohydrate 
content of the diet should be distributed as 10-15% at breakfast, 20-30% at lunch, and 
30-40% at dinner. Snacks should have 0- 10% of the total carbohydrates. 30-40% fat 
predominantly unsaturated fat, 20% protein 
 Medical Nutrition Therapy which is based on a proper  nutritional 
recommendations during maternity, with customization based on:  
 Nutritional assessment 
 Height 
45 
 
 Weight 
 Glycaemic control levels 
 
Goals:  
– Provision of  nutritionally perfect and needed diet for the pregnancy  
– Achieve a normoglycemic status 
Dietary education can have many benefits for women with GDM, including improved 
glycaemic control, appropriate weight gain and a permanent improvement in lifestyle. 
The ADA makes the following recommendation with regard to the management of 
women with GDM. 
I. Minimum of 175g of carbohydrate per day, with total carbohydrate intake 
<45% of total energy. 
II. Consistency in carbohydrate intake at meals and snacks change  from day-to-
day 
III. If obese a calorie-restricted diet (about 70% of the recommended daily caloric 
intake for pregnancy women),to slow weight gain without compromising the 
foetus or causing ketosis. 
IV. Research is limited regarding glycaemic index in women with GDM. 
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However there has been several recent studies regarding the role of glycaemic 
index in the management of women with GDM. A small Australian study randomised 
women with GDM to either a low glycemic index diet or conventional high-fiber (and 
higher-GI) diet, and found a reduction in the number of women reaching the criteria 
for commencing insulin in the low-GI group (29%vs59% ). However a substantial 
proportion of women in the high-fibre group were able to avoid insulin by 
subsequently changing to a low-GI diet.  
A second study, also conducted in Australia, randomised almost 100 womens 
with GDM to follow either a low glycemic index diet or a high-fiber (moderate –GI) 
diet, and found no difference in birthweight, prevalence of macrosomia, or need for 
insulin. However,both groups in this study actually achieved a relatively low-GI diet 
    Diabetic food pyramid 
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(possibly because all participants had already received dietary counselling prior to 
being enrolled), with only a modest difference between the groups in this regards at 
the end of the study, which may have accounted for the lack of effect seen. 
1b. Exercise 
Exercise improves the glycaemic control by improvising the insulin sensitivity 
specially at the area of skeletal musculature. Even a very minimal exercise (walking 
2.53km in 1hour) performed after having food is been shown to significantly reduce 
the 1-hour postprandial blood glucose levels.
26
 
A study of 64 pregnant women looked at the effectiveness of resistance exercise in 
GDM, and that a programme consisting of circuit-type resistance exercise with an 
elastic band for 30-40 min 2-3 times per week resulted in a reduced requirement for 
insulin (22% in the exercise group vs.56% in the control group). Also the exercise 
group had 80% of blood glucose levels in target more frequency (63% vs.41% of the 
time). The treatment was safe, with no cases of post-exercise hypoglycaemia, and no 
difference in caesarean section rate, macrosomia or preterm delivery. By contrast a 
previous, smaller study did not show any difference in the need for insulin with 
resistance exercise except in a subgroup of overweight women with GDM. 
 Prevention of Gestational Diabetes 
Weight loss prior to pregnancy would be predicted to reduce the risk of 
development GDM. The effect of exercise specifically was addressed in a meta-
analysis by tobias et al. This looked at observational studies of exercise either pre-
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pregnancy or early in pregnancy, and found that higher levels of physical activity were 
associated with a lower risk of developing GDM. Women who exercised the most pre-
pregnancy (by self-report) had a 55% lower risk of developing GDM, and the GDM 
was also reduced by 24% in women with the most exercise in early pregnancy. A 
small Australian interventional trial looked at the effect of an exercise programme on 
prevention of GDM. Although the intervention led to a reduction in fasting glucose at 
28wk and a reduced insulin level at 36wk, there was no difference found in estimated 
insulin resistance. The study was not powered to find a difference in GDM between 
the exercise group and the control group. 
A randomised trial of a multidisciplinary programme involving continuity of 
maternity care provider, weight assessment at each visit, a brief intervention by a food 
technologist and psychological assessment was to reduce the risk of GDM (6% vs 
29%) in the control group. It was also associated with less weight gain during 
pregnancy (7.0 vs 13.8kg) but no difference in birth weight of the infant was found. 
A single randomised controlled trial conducted in Finland has found that 
administration of probiotics to pregnant women reduced the frequency of gestational 
diabetes from 36% to13%. The reason for the very high rate of GDM seen in the 
control group in this study is unknown, other than that the investigators used relatively 
stringent diagnostic criteria for gestational diabetes (fasting glucose ≥4.8 mmol/1, 1-hr 
glucose ≥ 10.0 mmol/l, and 2-hr glucose ≥ 8.7 mmol/l ). More research in needed to 
confirm this finding. 
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CHOOSE SELF –MONITORING 
             Monitoring of home blood glucose is necessary in order to identify women  at 
increased risk of adverse perinatal outcomes and to determine the need for 
intensification of therapy, it has been shown to have a number of benefits for the 
mother and the fetus
27
. What is less clear is where to set targets for blood glucose in 
addition , the optimal frequency and timing of monitoring is still to be elucidated  
emerging areas  of research include the use of glycosylated  haemoglobin (Hba1c) and 
Contentious glucose monitoring systems(CGMS) 
            In many settings, it is common clinical practice to escalate therapy when two 
or more glucose measurements exceed the set thresholds in a 2 week period, but there 
is little data available to guide this. Also patients are often advised that they can 
reduce the frequency of monitoring after a period of time with all glucose measures 
with in target with dietary therapy alone. 
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TIMING OF GLUCOSE MONITORING 
The usual practice is to recommend monitoring of fasting levels with either 1-hour or 
2 –hour post-prandial levels. 
Fasting Blood glucose 
The HAPO study demonstrated an increase in advance perinatal outcomes with 
elevation of the fasting glucose alone on OGTT
28.
 An earlier study of women with 
treated GDM had showed a correlation between increasing levels of fasting glucose 
>95mg/dl and adverse neonatal outcome (57.9% if average fasting glucose above 95 
mg/dL). However the fasting glucose alone does not predict adequately the need to 
commence insulin therapy‖. 
Post-prandial  versus Pre-Prandial Blood glucose 
 Post prandial blood glucose monitoring has been suggested to be superior to 
pre-prandial in GDM. In a small study, fasting plus 1 hour postprandial monitoring  
was associated with better glycaemic control than pre-prandial monitoring {HbA1c 
6.5%vs 8.1%),and a reduced risk of neonatal hypoglycaemia (3% vs 21%),LGA 
infants (12% vs 42%) and caesarean delivery for cephalopelvic disproportion (12% vs 
36%). 
Of note these patients likely had overt diabetes rather than GDM, with mean 
fasting glucose on OGTT 137-145 mg/dl(7.6-8.0mmol/l). 
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 Post- prandial  glucose monitoring may be performed either one or two hours 
after a meal, with no clear benefit for either approach at present.(39)  In a study 
utilising continuous glucose monitoring in women with treated GDM, post-prandial 
glucose peaked at approximately 90 minutes, with marked inter individual variation. 
Half of patients still had elevated levels after 3 hours. In this study there was no 
disparity at different meals, but another study found higher 1-hour levels after 
breakfast and 2-hours levels after lunch and dinner. In pregnant patients without 
GDM, the time to peak glucose seems to be shorter, at approximately 70 minutes in a 
separate study. 
GLUCOSE TARGETS 
Fasting plasma blood glucose level <= 95mg/dl(5.3mmol/l) 
1-Hr post-prandial plasma glucose level<=140mg/dl(7.8mmol/l) 
 2-hr post-prandial plasma  glucose level<=120mg/dl (6.7mmol/l) 
However, studies in normal (non-obese) pregnant women have suggested that 
physiological glucose levels are significantly lower than this. one recent meta-analysis 
found average glucose levels at 34 weeks gestation in pregnant women of normal 
weight and glucose tolerance to be: fasting 71+(or) _8 mg/dl (3.9+_0.4mmol/l), 1-
hour 109+(or)_13 mg/dl (6.1+_0.7mmol/l), and 2-hour 99+_10mg/dl(4.9+_0.6 
mmol/l). It was suggested that postprandial targets could be based on levels one 
standard deviation above the mean, resulting in a 1-hour post prandial targets 
of<122mg/dl (6.8mmol/l) and a 2-hour target of<110 mg/dl (6.1mmol/L). Data from 
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the HAPO study supports a lower fasting glucose targets of <92 mg/dl (5.1mmol/l), as 
at this level the risk of a large for gestational age infant or cord blood C-peptide 
>=90
th
 percentile is increased by 75%. 
A significant concern with lowering glucose targets in GDM is a potential 
increase in the risk of small for gestational age (SGA) infants. Langer found in 1989 
that women with treated GDM with the average glucose values 86mg/dl (4.8mmol/l) 
had an increased incidence of SGA infants (20%, compared to 11%in a control group 
without GDM). In the >= same study, patients with a mean blood glucose level 
between 87-104 mg/dl (4.8-5.8mmol/l) had risks of metabolic complications 
comparable to the control group, whereas above that level the risk of LGA infants 
significantly increased. 
The risk of SGA infants is of particular concern if there is a history of vascular 
disease, smoking, or hypertension, as well as in patients with overt or pre-existing 
diabetes, due to the risk of placental insufficiency in these patients. Lower therapeutic 
glucose targets might therefore not be appropriate in such patients. 
An additional factor occasionally affecting birth weight is the glucokinase 
mutation (MODY 2). This results in life- long mild hyperglycaemia due to altered 
glucose sensing by the beta cell, and is inherited in an autosomal dominant manner. 
Birth weight is lower in fetal mutation.And higher in maternal mutation, with this 
effect being additive. There is only a significant effect on birth weight when the 
mother and foetus are genetically discordant. in addition, tight control of fasting 
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glucose in an affected mother may ameliorate the risk of macrosomia for an 
unaffected foetus but will increase the risk of growth restriction of an affected foetus. 
 
2. PHARMACOTHERAPY 
INSULIN 
Insulin is a standard treatment for a lot many years for gestational diabetes. 
However, in a recent research has focused on  safety of the latest insulin analogs in 
pregnancy. These are an attractive option due to more convenient timing of 
administration (aspart, lispro) and a lower risk of hypoglycaemia (glargine). 
There were concerns that due to its increased affinity for the insulin-like 
growth factor (IGF) receptor, the long acting insulin analogue glargine might lead to 
increase mitogenic effects and foetal growth. A systematic review and meta analysis 
of 8 studies looking at patient with glargine versus NPH insulin for GDM or pre-
gestational diabetes found no evidence of an increase in adverse foetal outcomes. In 
particular, there was no increase risk of LGA infant in women using glargine (risk 
ratio 1.02). All studies reviewed in this Meta analysis were observational cohort 
studies, with no randomised controlled trials available. 
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 Insulin and their action 
Type of      Insulin Generic 
Name 
Onset Peak Duration 
Rapid-acting Lispro, 
Aspart 
15 min 30-90 min 3-5 hrs 
Short acting Regular  30-60 min 2 hrs 5-8 hrs 
Intermediate acting  NPH 1-3 hrs 8 hrs 12-16 hrs 
 
In the only prospection observational study of glargine compared to NPH 
insulin in women with gestational and pre-gestational diabetes, glargine was 
associated with a decreased risk of mild and frequent hypoglycaemia compared to 
NPH and was not associated with any increased in adverse  outcomes. Infact and 
admission to neonatal ICU in the glargine group, although the overall numbers were 
very small.
29 
The majority of patients respond to continuation of treatment with glyburide 
plus a single injection of glargine insulin (Lantus) in the morning or NPH at night 
time before night food. The rationale for choosing a combination of oral 
hypoglycemic agent and insulin is that insulin can properly suppress hepatic 
neoglucogenesis, which is the main cause of elevated fasting hypoglycemia
.30
. 
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Continuous subcutaneous insulin infusion 
CSII: Administration of the rapid-acting insulin via insulin pump 
• Safety and a reliable method for satisfying the basal insulin needs in the pregnant 
patients with Insulin Dependent Diabetes Mellitus during antenatal periods. 
• The insulin pump is a battery powered system, which may be weared during the most 
of the daily routine work.  
• These units supply a continuous shorter acting insulin therapy through the 
subcutaneous infusion method.  
• The basal infusion rate and bolus dose to cover meals are determined by frequent self-
monitoring of blood glucose. The bal infusion rate is close to 1u/hr. 
– Can be used to effectively mimic physiologic insulin secretion 
– episodes of hypoglycaemia can be reduced. 
– No significant difference in glycemic control for pregnancy outcomes 
with CSII versus multiple-dose insulin (MDI) therapy 
• Insulin aspart and lispro are the standard of care for CSII 
• Disadvantages of CSII:  
– Complexity–requires counseling and training  
– Cost  
– Potential for insulin pump failure/user error or infusion site problems  
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ORAL HYPOGLYCAEMIC AGENTS 
Although insulin is the traditional first-line management  for GDM when 
nutrition therapy fails, the proper use of oral hypoglycarmic agents in the treatment of 
GDM is appealing to patients and providers  probably due to easy to administer, in the 
past concern existed about teratogenicity and the risk of hypoglycaemia in the infant 
due to placenta  transfer of  oral  agents. Despite not being endorsed by several major 
organisations the use of oral hypoglycaemic agents for management of GDM is 
popular and widespread in clinical practice.  
Safety 
Glyburide has been the sulfonylurea most frequently studied in GDM treatment 
.conflicting studies have been published regarding transfer of glyburide across the 
placenta ,with an vitro study demonstrating minimal placenta transfer .42 however ,a 
more recent study done in vivo demonstarted significant transfer across the placenta at 
term ,with an average glyburide umbilical cord to maternal plasma concentration ratio 
at the time of delivery of 0.7+-0.4.43 the reason given for this substantially different 
finding was an improved assay using liquid chromatography/mass spectrometry. 
Despite placental transfer ,glyburide appears to be safe for the foetus upto a maternal 
dose of 10mg BD
31
. 
Studies of the risk of congenital anomalies with sulfonylurea have often been 
done in women with type 2 diabetes rather than GDM and have been confounded by 
the presence of poor glycaemia control .one study of 332 infants born to mothers with 
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type 2 diabetes found that there was no difference in rates of anomalies with different 
form of diabetic treatment in the first trimester(diet, insulin or sulfonylurea)but 
maternal HbA1c at the initial presentation was directly related to the risk of major 
malformation
32
. 
Metformin is known to cross the placenta freely ,but as it improves insulin 
sensitivity and does not cause hypoglycaemia this is considered by many clinicians 
not to be major concern. A study of 90 women with polycystic ovarian syndrome 
whom conceived while taking metformin reported  safty for the mother and foetus 
with no increased risk of foetal anomalies pre eclampsia birth weight and maternal 
and neonatal  hypoglycaemia compared to a control group.46 there have also not be 
any safety concerns in several treatment trials of metformin for gestational diabetes .  
  
EFFICACY 
Dhulkotia et al conducted a meta-analysis comparing oral hypoglycaemic agent 
(OHAs) to insulin for the management of GDM. This included trials of both glyburide 
& metformin, resulting in significant heterogeneity. However overall there was no 
significant difference in fasting or post-prandial blood glucose level between OHAs 
and insulin. Birth weight was slightly lower with metformin,& higher in glyburide 
studies, but overall there was no significant difference of LGA or SGA infants, 
admission to neonatal ICU, neonatal respiratory distress, birth injury, preterm birth, 
congenital anomalies, intrauterine foetal death, maternal hypertension disorders or 
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caesarean section. Maternal hypoglycaemia occurred in 8.8% of patients in the OAH 
groups compared to 22.2% in the insulin group, but this was not statistically 
significant and was also quite variable due to the difference between metformin and 
glyburide. 
In an RCT by larger et al 400 women were assigned to receive either glyburide 
or insulin when intensification of treatment was required for GDM. Mean blood 
glucose level during treatment were 105mg/dl (5.9 mmol/l) in both glyburide and 
insulin groups. No significant differences were found in terms of incidence of LGA 
infants,macrosomia lung complication neonatal hypoglycaemia, admission to neonatal 
ICU or congenital anomalies. In this study only 4% of patients required the addition of 
insulin to glyburide,although baseline glucose  level were not very high with average 
pre-treatment blood glucose 114mg/dl (6.4mmol/l)
33
. 
 
A recent retrospective cohort study of over 10000 women treated for GDM in 
California did found that neonatal born to women with gestational diabetes managed 
with glyburide had an increased risk of macrosomia (odds ratio 1.29) and admission to 
neonatal ICU (odds ratio 1.46). 39% of women initially on glyburide in this study 
eventually started insulin. However there are obvious limitations to this retrospective 
study design with the non-random allocation of treatment meaning that patient and 
caregiver preference may have led some women to glyburide despite insulin being 
indicated. Glycaemic control was not reported in this study. Women with a lower 
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level of education or who didn‘t speak English as their primary language were more 
likely to receive glyburide than insulin. 
 
 METFORMIN 
The metformin in a  gestational diabetes – MiG  trial was a randomised, open-
label trial that assigned women with GDM at to either metformin,with insulin added if 
required or insulin alone
34
. 
 It found no increase in the primary outcome (a composite of neonatal 
hypoglycaemia, respiratory distress, need for phototherapy, birth trauma, 5-min Apgar 
score<7, or prematurity) in those on metformin compared with insulin alone (32% vs 
32.2%). There was also no difference in any secondary outcomes , including 
admission to neonatal  ICU neonatal hypertensive complication. 
  The only significant difference in individual components of the primary 
outcome was increased neonatal hypoglycaemia, (<28.8mg/dl, 1.6 mmol/l)in  the 
insulin group (8.1% vs 3.3%)and an increase in preterm birth <37 wk in the 
metformin group (12.1% vs 7.6%) the latter was not clinically significant with mean 
gestational age at delivery 38.3 wk in the metformin group vs 38.5 wk in the insulin 
group. 
Almost half the metformin patients needed to have insulin added at some point 
with baseline BMI and glucose level predictive of the need to start insulin. However 
metformin therapy was associated with a number of benefits, including a reduced dose 
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of insulin required (42 units vs 50 units per day in those of insulin) and increased 
acceptability (76.6% said they would choose to receive this treatment again vs 27.2% 
in the insulin group) patients taking metformin gained less weight from enrolment to 
the postprandum visit (8.1 kg vs 6.9kg). There was a low risk of adverse effects, with 
8.8% of women on metformin developing gastrointestinal side effect, but in most 
cases only dose reduction rather than cessation was required. 
Therefore the overall conclusion of the MiG trial was that metformin either 
alone or in combination with insulin, is safe and effective as a treatment for 
gestational diabetes, with benefits including patient acceptability & reduced weight 
gain. A follow-up study is planned to further assess safety with assessment of the 
infants at 2 years of age. 
Another study done in Finland was an open-label prospective randomised 
controlled trial that allocated 50 women to either metformin or insulin for GDM not 
controlled by diet alone. Overall there were no significant difference in incidence of 
LGA infants, mean birth weight, at neonatal morbidity between the groups, in this 
study 31.9% of women on metformin needed supplemental insulin as well as 
metformin & either need for GDM were predictive of the need for supplemental 
insulin. 
METFORMIN VERSUS GLYBURIDE 
A Relatively small study by Moore et al has compared metformin to glyburide for 
GDM in patients not achieving glycaemic control on diet therapy. Significantly more 
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patients in the metformin group did not achieve adequate glycaemic control (34.7% vs 
16.2%). However in patient who did achieve glycaemic control, there was no 
significant difference between the mean fasting & 2-hr post-prandial glucose levels. 
Another small study looking at this issue in 2010 found that the only difference in 
outcome between patients treated with glyburide versus metformin was less maternal 
weight gain in the metformin group (10.3 vs 7.6 kg) with no difference in the 
requiremewnt for insulin (both groups around 25%). 
Given limited data on this  issue, as in the non-pregnant diabetic population,in 
general metformin is preferred because of reduced weight gain and a lesser risk of 
maternal hypoglycaemia. There have been no studies examining combination therapy 
with metformin and a sulfonylurea for GDM. Increasing evidence suggests that 
metformin is a safe effective treatment option in gestational diabetes. 
 
ADJUSTING TREATMENT BASED ON FETAL ULTRASOUND 
PARAMETERS 
The rationale for approach is that even with strict control of GDM there is still 
an increased risk of macrosomia in some infants
35
.whilst some foetuses may be at 
riskof grouth restriction in this situation due to excessively tight maternal glucose 
control
.36
 
Initial studies focused on measuring insulin levels in amniotic fluid as a marker 
of foetal hyperinsulinism, which is thought to be the main driver of foetal 
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complications of maternal GDM. Due to the impracticality of this approach, 
subsequent studies assessed foetal abdominal circumference (AC) on ultrasound scan 
(USS) with an AC >75
th
 percentile correlating well with high amniotic fluid insulin 
levels. There have been four RCTs that have addressed this. 
The most recent study in 2004 randomised 229 women to conventional treatment 
of GDM with glucose targets <90 mg/dl (5.0 mmol/l) fasting and <120mg/dl 
(6.7mmol/l) 2-hr post-prandial, or modified treatment targets based on abdominal 
circumference on foetal ultrasound done bi-weekly. 
I. AC ≥ 75th percentile : fasting <80 mg/dl (4.4mmol/l) and post-prandial 
<100mg/dl (5.5mmol/l) 
II. AC <75th percentile : fastine <100mg/dl (5.5mmol/l) and post-prandial 
<140mg/dl (7.8mmol/l) 
 
This modified treatment resulted in a significant reduction in the percentage of 
LGA infants (7.9 vs 17.9%), SGA infents (6.0 vs 9.0%) and macrosomia (3.3 vs 
11%). 
In another study published in the same yr the standard therapy group had the same 
glucose targets, and patients in the ultrasound-guided therapy group had targets of <80 
mg/dl (4.4mmol/l ) fasting and <110mg/dl (6.1mmol/l )2-hr post-prandially only if the 
foetal abdominal circumference (AC) was >75
th 
percentile. If however the AC was 
<75
th
 percentile, insulin was only commenced if there was severe hyperglycaemia 
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with fasting glucose >120mg/dl (6.7mmol/l) or post-prandial glucose >200 mg/dl 
(11.1mmol/l) and in fact no patients met these criteria. 
Perhaps due to these much higher targets, this study did not detect any difference 
in incidence of LGA or SGA infants. However there certainly was not an increase in 
either of these outcomes, despite allowing significant untreated hyperglycaemia, and 
there was also no increase in caesarean section or neonatal hypoglycaemia. 
Two study were done in US. One assigned patients with elevated fasting glucose 
levels in pregnancy to an ultrasound-guided group receiving insulin only if the AC 
was ≥70th percentile or the fasting glucose was >120mg/dl (6.7mmol/l). Compared to 
a control group treated with insulin, there was no significant difference in average 
birth weight, incidence of macrosomia or neonatal morbidity in the ultrasound-guided 
group. Caesarean section was lower in the control group (14.6 vs 33.3%), but this was 
not explained by birth weight. 
The other US trial randomised patients with foetal AC on USS ≥75th percentile to 
either diet therapy or intensive therapy with diet and insulin and strict glucose targets 
(<80mg/dl/4.4mmol/l)fasting and <110mg/dl/6.1mmol/l post-prandial). Intensive 
treatment of these high risk patients was found in a third group treated with diet and 
no monitoring on the basis of a low risk foetal ultrasound with AC <75
th
 percentile. 
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11. FETAL SURVEILLANCE AND TIMING OF DELIVERY 
In addition to its potential role in guiding the intensity of glucose lowering 
treatment, fetal ultrasound is frequently used to estimate fetal weight and well-being 
and to assist in determining the timing for delivery. 
There is a paucity of high level evidence on the optimum gestational age for 
delivery in gestational diabetes and many units have extrapolated from the 
management strategies for pre-gestational or pre-existing diabetes. 
The experience reported by the diabetes unit at the national maternity hospital 
Dublin in 1983 and again in 1992 is particularly instructive. They noted that the only 
deaths in normally formed infants occurred when there was clinical evidence of foetal 
macrosomia, polyhydramnios or poor metabolic control. Consequently in their 
absence, this group of experienced clinicians allowed the otherwise uncomplicated 
pregnancies to go to full term (40 completed weeks of gestation
37
 
 Of more than passing interest is that their caesarean section rate was 7% & normal 
vaginal delivery occurred in 90.5%. 
Likewise there is no high level evidence on the place of cardiotocographic 
foetal monitoring in the absence of other obstetric indication such as foetal growth 
restriction and the hypertensive disorders. The current protocols are largely empiric 
and driven by expert opinion. The report of landon et al which considered women 
with type I diabetes, noted that foetal surveillance most commonly led to in tervention 
in women with associated vascular disease, such as hypertention or nephropathy. 
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Gabbe and colleagues recommended that in uncomplicated GDM pregnancies, CTG 
monitoring should be commenced after 40 weeks gestation whilst awaiting 
spontaneous onset of labour
38
 
 However there is again a paucity of high level evidence in this area to guide the 
clinician. 
A Cochrane review published in 2001 found that there was only one 
randomised controlled trial
39
 comparing panned elective delivery at 38 weeks 
gestation vs expectant or awaiting the onset of spontaneous labour up to 42 weeks 
gestation, with twice weekly CTG & amniotic fluid volume surveillance. This trial 
includes a range of insulin treated women, rather than simply women with gestational 
diabetes. The review concluded that induction at 38 weeks did not result in an increase 
in caesarean section RR 0.81 (95% CI 0.52-1.26) however the risk of macrosomia 
(birth weight ≥4000g) was lessened in the elective delivery group RR 0.56 (95% CI 
0.32-0.98) and there were three cases of mild shoulder dystocia in the expected group. 
The authors concluded that there was insufficient evidence to make a conclusive 
recommendation. 
MODE OF DELIVERY 
The major concern for vaginal delivery in the women with gestational diabetes 
is the potential risk of shoulder dystosia , in particular brachial plexus palsy. What 
ultimately determines if the foetal shoulders will pass readily through the maternal 
pelvis in the dynamic interaction between the maternal pelvic girdle, the strength of 
66 
 
the uterine contractions and the mother‘s expulsive efforts and the foetal diameters, 
none of which can be reliably measured and / or predicted. 
Although increasing, foetal weight  positively  coorelates with an increasing 
risk of shoulder dystosia, as many cases occur in babies with birth weight less than 
4000g as those who are classified as being macrosomic (ie birth weight >4000g) 
furthermore 50% of cases of brachial plexus palsy occur in the absence of shoulder 
dystosia, suggesting that ante and intra partum factors also play an important 
aetiological role in its genesis.  
 
12. POSTPARTUM 
There is a sharp fall in the patient`s insulin requirements immediately after 
delivery. For insulin dependent diabetics, the usual practice is to start them on about 
half the dose of insulin before delivery, or the pre-pregnancy dose. If the patients have 
delivered by caesarean section, rapid-acting insulin may be used to treat glucose levels 
greater than 140-150 mg/dl by multiple dose injections or continuous insulin infusion 
until she is orally allowed. Gestational diabetics controlled on diet alone can revert to 
their normal diet postpartum, and those who needed insulin during pregnancy usually 
do not require it any longer. 
All gestational diabetics should be advised to have fasting blood sugar tested at 
6 weeks, and annually thereafter
40..
  
They should be counselled regarding diet, exercise and weight reduction which 
can reduce their chances or delay developing type 2 diabetes later. 
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BREASTFEEDING 
Early breastfeeding, within 30 minutes of birth, and every 2- 3 hours, also helps in 
reducing the risk of neonatal hypoglycaemia. Women with pre-existing diabetes can 
resume or continue to take metformin and glibenclamide while breastfeeding but other 
oral hypoglycaemic agents should be avoided. 
 
CONTRACEPTION 
Copper intrauterine devices, barrier methods, and natural family planning 
methods can be used without restriction in all diabetics (type 1 and 2). Though there 
has been a concern regarding an increased risk of infection and pelvic inflammatory 
disease with the use of intrauterine decices in diabetics, there is no evidence to support 
such fears. The World Health Organization advises unrestricted use of copper 
intrauterine devices in all types of diabetics. 
Women with diabetes mellitus and nephropathy, retinopathy, neuropathy, or 
other vascular disease are not advised to use progesterone injectables, COCs, 
combined contraceptive patch and the vaginal ring.
41
 
A permanent method of contraception like tubal ligation can be offered but 
should be undertaken with caution in those with vasculopathy and hypertension. 
          Thus the importance of gestational diabetes in obstetric practice has evolved 
rapidly with the global increase in maternal obesity and age at delivery. New 
diagnostic criteria have been developed to align the diagnosis of gestational diabetes 
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with adverse pregnancy outcomes in particular those associated with excess foetal size 
and adiposity. 
Whilst universal acceptance of the new diagnostic strategies has yet to be 
achieved, widespread recognition of the value of a uniform approach to diagnosis & 
classification of hyperglycaemia in pregnancy in evolving. 
New frontiers in treatment include the potential role of oral hypoglycaemic 
agents and the use of ―customised‖ glycaemic treatment targets adjusted according to 
assessments to foetal growth. 
Evidence in the area of optimal foetal surveillance timing and mode of delivery 
remains sparse, with clinical decisions based more on local preferences and protocols 
than on high level evidence. 
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AIM  
AIM 
To find association between first trimester fasting blood sugar value compared 
with the second trimester oral glucose tolerance testvalue (75gm DIPSI criteria) for 
diagnosis of GDM. To find the efficiency of FBS and BMI as a screening test for 
GDM. 
 
 
                         
               
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
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                                            MATERIALS AND METHODS 
MATERIALS AND METHODS 
       
      The study was conducted in the department of Obstetrics and Gynaecology, PSG 
Hospitals, Coimbatore from June 2014 – May 2015.The study period was 12 months. 
 
STUDY DESIGN 
Prospective Observational Study 
 
STUDY POPULATION 
270 antenatal patients having antenatal follow up from 1
st
 trimester in the department 
of Obstetrics & Gynaecology, PSG IMSR & Hospitals, Coimbatore. 
INCLUSION CRITERIA: 
 All antenatal patients from  first trimester of  pregnancy 
 Singleton pregnancy 
EXCLUSION CRITERIA: 
 Pregestational diabetes mellitus 
 Patient who lost follow up for OGTT testing during 2nd trimester. 
 Patients with first trimester FBS more than 105mg/dl 
 Antenatal patients on long term steroids for medical disorders 
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METHODOLOGY 
The study was initiated after obtaining approval from the ethics committee in 
PSG IMSR. 
 
The patients selected were according to the inclusion criteria- antenatal patients 
from first trimester without having pre-existing diabetes mellitus and oral and written 
consent were obtained. 
Patients who had not turned up for OGTT during the second trimester or who 
were not willing to participate in the study were excluded. 
Basic assessment of their risk factors was already done in the first antenatal 
visit along with detailed family history. Their height and weight was measured. 
Weight was noted at the time of first visit. BMI was calculated form the first visits 
data. Gestational age was noted for both the tests during first and second trimester.  
About 270 antenatal mothers were selected during their first trimester from 
Obstetrics & Gynaecology department OPD during june 2014- may 2015 were 
explained about the study after excluding other women who were not eligible for the 
study and fasting blood glucose levels were measured and documented. The patients 
were followed up during the second trimester and a 75 gms OGTT was done and the 
levels were noted 
All the patients were asked to follow unrestricted carbohydrate diet and not to 
change the diet pattern and fasting blood glucose was tested during the first trimester 
with overnight fast of atleast 8 hours. 
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During second trimester , when the patients entered the hospital for second 
trimester OGTT irrespective of the last meal given, 75gms oral glucose mixed in 150 
ml of water and blood test taken 2 hrs later according to the DIPSI criteria. All the 
patients were instructed not to have meals after the 75gm glucose ingestion. 
If the patient experienced nausea during the drinking procedure a pinch of fresh 
lime was added. If she had vomited after glucose ingestion then the testing is done at 
the further time of the day or asked to come on the following day for re-testing and the 
same procedure is followed. The patient is requested not to have meals in between and 
venous blood was collected 2 hrs later.  
Two ml of venous blood was collected in sterile fluride vial. These samples 
were centrifuged at 3500 rotation per minute for 10 minutes. Plasma was used for 
estimation. Blood test should be done within 3 hours of collection.using autoanalyser 
Cobas Integra 400 plus-Roche diagnostics by glucose hexokinase method using 
spectrometric assay. It has analytical sensitivity of 0.59mg/dl and test range of upto 
720mg/dl.  
 
Test Principle: 
Hexokinase catalyses the phosphorylation of glucose by ATP to form glucose 6 
phosphate and ADP. To follow the reaction, a second enzyme glucose 6 phosphate 
dehydrogenase is used to catalyse oxidation of  glucose 6 phosphate by NAD+ to form 
NADH 
D Glucose+ATP     HK  D Glucose 6 phosphate+ADP 
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D Glucose 6 phosphate+NAD + G6PD   D-6-Phosphogluconate+NADH+H+ 
 
             The concentration of NADH formed is directly proportional to glucose 
concentration. It is determined by increase in absorbance at 340nm. 
  Patients with first trimester fasting blood glucose levels were categorised as 
<92 mg/dl ,  92-105 mg/dl were included,  >105 mg/dl were excluded from the study. 
` Patients with FBS <92 mg/dl were subjected to second trimester 75 gms 
OGTT. Patients with FBS between 92-105 mg/dl were subjected to diabetic diet ,FBS 
and PPBS was done after 2 weeks of diabetic diet and if it was found to be normal, 
they were subjected to second trimester 75 OGTT DIPSI criteria. If FBS, PPBS after 2 
weeks of diabetic diet were high they were not subjected to second trimester OGTT 
and were excluded from the study.Patients with FBS of  >105 mg/dl were excluded 
from the study 
First trimester FBS value and second trimester 75 gms GTT values were 
analysed and the results were tabulated. Correlation between first trimester FBS, 
BMI  versus second trimester OGTT were done. Women diagnosed as GDM were 
managed appropriately. 
Screening property of both fasting blood sugar and BMI were calculated and 
compared using receiver operating characteristic (ROC) curves.  
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RESULTS AND ANALYSIS 
 
BASE LINE CHARACTERISTICS OF THE STUDY GROUP 
Table-1: AGE DISTRIBUTION  
AGE 
NUMBEROF 
PATIENTS 
PERCENTAGE 
<20 11 4.07 
20-29 209 77.40 
30-34 43 15.92 
>35 7 2.59 
 
 
 
Out of 270 patients, 11 patients were under age of  20 years 
                              209 patients were in the age of 20-29 years 
                              43 patients were in the  age of 30-34 years 
                              7 patients were in the age  of 30-34 years 
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  Table 2. PARITY DISTRIBUTION  
 
Parity Number of patients PERCENTAGE 
Primi gravida 130 48.14 
Multi gravida 140 51.85 
 
 
 
Out of 270 patients , 130 patients were primigravida 
                                  140 patients were multigravida 
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Table 3. WEIGHT DISTRIBUTION 
BMI 
NUMBER OF 
PATIENTS 
PERCENTAGE 
<18.5 45 16.66 
18.5-24.9 147 54.44 
25-29.9 58 21.48 
30-34.9 17 6.29 
>35 3 1.11 
 
 
Out of 270 patients , 45 patients were under BMI of  18.5 
                                147 patients were in BMI of  18.5-24.9 
                                  58 patients were in BMI of  25-29.9 
                                  17 patients were in BMI of  30-34.9 
                                    3 patients were above the BMI of  35 
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Table 4: FAMILY H/O DISTRIBUTION 
FAMILY H/O NUMBER OF PATIENTS PERCENTAGE 
NIL FAMILY H/O 222 82.22 
POSITIVE FAMILY H/O 48 17.77 
 
 
Out of 270 patients , 222 patients had no family history of diabetes mellitus 
                               48 patients had positive family history of diabetes mellitus 
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Table  5. FASTING BLOOD GLUCOSE DISTRIBUTION 
FBS 
NUMBER OF 
PATIENTS 
PERCENTAGE 
<92 169 62.59 
>=92 101 37.40 
 
 
 
 
 
 
 
 
Out of 270 patients , 
            169 patients had Fasting Blood Glucose <92 mg/dl 
            101 patients had Fasting Blood Glucose >=92 mg/dl – 105mg/dl 
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Table  6. OGTT DISTRIBUTION 
OGTT 
NUMBER OF 
PATIENTS 
PERCENTAGE 
<=120 214 79.25 
121-140 41 15.18 
141-200 14 5.18 
>200 1 0.37 
 
 
 
Out of 270 patients , 214 patients had OGTT <=120 mg/dl 
                                  41 patients had OGTT between 121- 140 mg/dl 
                                  14 patients had OGTT between 141- 200 mg/dl 
                                  1  patient had OGTT more than 200 mg/dl 
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STATISTICAL ANALYSIS 
 
1. First trimester FBS as a screening test for GDM . 
2. BMI as a screening test for GDM  
3. BMI as a comparison for GDM  
4. Age  as a comparison for GDM  
5. Family h/o as a comparison for GDM 
6. First trimester FBS as a comparison for GDM 
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 Table 7. FIRST TRIMESTER FBS AS A SCREENING TEST FOR GDM 
(STATISTICAL CONSOLIDATED DATA) 
I TRIMESTER FBS  AS A SCREENING TEST FOR GDM 
         
FBS LEVEL 70 75 80 85 90 95 100  
PATIENTS  > 
THRESHOLD VALUE 
NUMBER OF 
CASE 
270 268 257 223 135 67 22 
% 100 99.2 95.1 83 50 24 8.14 
PAT IENTS WITH 
GDM > THRESHOLD 
VALUE 
NUMBER OF 
CASE 
15 15 15 15 13 5 1 
FALSE POSITIVE 
RATE 
% 100 99 91.7 81.6 47.9 24.4 8.3 
SENSITIVITY % 100 100 100 100 86.6 33.3 6.6 
SPECIFICITY % 0 0.78 8.3 18.9 52.1 75.6 91.7 
PPV % 5.5 5.6 5.8 6.7 9.6 7.5 4.5 
NNP % 100 100 100 100 98.5 95 94.4 
 
Patients with FBS>90 had sensitivity of 86.6%, specificity of 52.1%, positive 
predictive value of 9.6%, negative predictive value of 98.5% 
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Table 08. I TRIMESTER BMI AS A SCREENING TEST FOR GDM 
(STATISTICAL CONSOLIDATED DATA) 
I TRIMESTER BMI  AS A SCREENING TEST FOR GDM 
            
BMI 20 22 24 25 26 27 28 29 30 35 
PATIENTS  > 
THRESHOLD 
NUMBE
RS 
199 129 92 78 58 40 30 25 20 3 
% 73.7  47.7 34 28.9 21.5 14.8 11.1 9.25 7.4 1.1 
PATIENTS 
WITH GDM > 
THRESHOLD 
NUMBE
RS 
14 11 9 8 4 3 3 3 2 0 
FALSE 
POSITIVE RATE 
% 72.5 46.3 32.5 27.5 21.2 21.2 10.6 8.6 7.1 1.2 
SENSITIVITY % 93.3 73.3 60 53.3 26.7 20 20 20 13.3 0 
SPECIFICITY % 27.5 53.7 67.5 72.5 78.8 78.8 89.9 91.4 92.9 98.9 
PPV % 7 8.5 9.8 10.2 6.9 7.5 10 12 10 0 
NNP % 98.6 97 96.6 96 94.8 94.7 95 95.1 94.8 94.3 
 
 
Patients with BMI >24 had sensitivity of 60%, specificity of 67.5%, positive 
predictive value of 9.8%, negative predictive value of 96.6%. 
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REFERENCE OPERATIVE CHARECTERISTIC CURVE 
 
Area under curve for FBS=0.694 
Area under curve for BMI=0.63 
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Table 9. BMI AS A COMPARISSON FOR GDM (CROSS TAB) 
                 
BMI  AS A COMPARISON FOR GDM (CROSS TAB)  
      
BMI VS GDM 
OGTT 
TOTAL 
NORMAL GGI GDM OVERT 
BMI <25 165 22 7 1 195 
BMI >=25 49 19 7 0 75 
TOTAL 214 41 14 1 270 
 
P value <0.01 
 
BMI <25 
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BMI>= 25 
 
 
Out of 270 patients, patients who had BMI<25 had more normal values. 
Patients who had BMI >=25 had increased GCT values. This data was found to be 
statistically significant. 
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Table 10. AGE AS A COMPARISSON FOR GDM (CROSS TAB) 
                                        
 
AGE AS A COMPARISON FOR GDM (CROSS TAB)   
      
 
AGE VS 
GDM 
OGTT 
TOTAL 
 
NORMAL GGI GDM OVERT  
AGE <25 93 15 5 1 114  
AGE >25 121 26 9 0 156  
TOTAL 214 41 14 1 270  
 
P value =3.516 
AGE < 25 
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AGE > 25 
 
 
 
Out of 270 patients, Patients who had >25 years had more chances of developing GGI, 
GDM. (The data was not statically significant). 
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Table 11. FAMILY H/O AS A COMPARISSON FOR GDM (CROSS TAB)  
FAMILY H/O AS A COMPARISSON FOR GDM (CROSS TAB)  
      
 
FAMILY H/O VS 
GDM 
OGTT 
TOTAL 
 
NORMAL GGI GDM OVERT  
FAMILY H/O + 182 30 9 1 222  
FAMILY H/O -- 32 11 5 0 48  
TOTAL 214 41 14 1 270  
 
P value = 0.080 
FAMILY H/ O +  
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FAMILY H/O –  
 
  
Out of 270 patients,  
Patients who had positive family history had more chance of developing GGI, GDM. 
(The data was not statically significant). 
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Table 12. FBS AS A COMPARISSON FOR GDM (CROSS TAB) 
                 
FBS  AS A COMPARISSON FOR GDM (CROSS TAB) 
      
FBS VS GDM 
OGTT 
TOTAL 
NORMAL GGI GDM OVERT 
FBS <92 137 23 9 0 169 
FBS >=92 77 18 5 1 101 
TOTAL 214 41 14 1 270 
 
P value =0.455 
FBS < 92 
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FBS >=92 
 
 
. In groupI patients with FBS <92 were 169 patients, of which 23 developed 
GGI , 9 developed GDM 
In group II FBS>=92-105 were 101 patients out of which 18 patients developed 
GGI, 5 patients developed GDM, 1 patient developed overt diabetes respectively. 
Group II patients were subjected to diabetic diet earlier in view of initial high sugar 
values. So analysing the outcomes, we inferred that starting diabetic diet earlier has a 
significant role in decreasing the risk of developing GDM in advanced pregnancy. 
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RESULT 
Mean calculated continuous variable.Percentage calculated for categorical 
variable (sensitivity).Pearson chi –square test was used to find association between 
categorical variable. 
In addition sensitivity, specificity, false positive, false negative were 
calculated.Receiver operating characteristic (ROC) curve was plotted to find cut off 
value for FBS & BMI for GDM. 
Further Area under Curve (AUC) was calculated to observe discriminatory 
power between FBS & BMI FBS has little more discriminatory power in identifying 
GDM than BMI.P value <0.05 was considered statistically significant 
All statistical analysis was done using SPSS Software (statistical package for 
social sciences) With a threshold of FBS>90, sensitivity of 86%, specificity of 52%, 
hence FBS >90mg/dl can be considered as a threshold value for predicting  GDM 
which is lesser than the threshold 92 mg/dl which is already considered as a cut off for 
prediction of GDM With a threshold of BMI>24, sensitivity of 60%, specificity of 
67.5%, hence BMI >24  is a good predictor of GDM. 
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DISCUSSION 
 
A Prospective Observational Study was conducted in PSG Hospital, 
Coimbatore in the Department of Obstetrics & Gynaecology from June 2014 – May 
2015. 
A total number of 270 antenatal women having antenatal follow up from 1
st
 
trimester in the department of Obstetrics & Gynaecology PSG IMSR & Hospitals, 
Coimbatore were enrolled in the study.  
All patients selected according to inclusion criteria. Patients who had not 
turned up for OGTT  during the second trimester or who were not willing to 
participate in the study were excluded. 
For all patients fasting blood glucose was taken at first trimester. Patients with 
FBS <= 105 mg/dl were included in the study.FBS <92 mg/dl were considered to have 
normal sugar value and were subjected to OGTT by DIPSI criteria at second trimester. 
FBS-92-105mg/dl were subjected to diabetic diet and FBS, PPBS-were done after 2 
weeks, if FBS, PPBS values were normal, they were included in the study and 
subjected to OGTT at second trimester. If FBS, PPBS were high these patients were 
excluded from the study and subjected to treatment.  Patient with FBS >105 mg/dl 
were excluded from the study and was started on treatment and were not subjected to 
OGTT at second trimester.BMI was also calculated for these patients at first visit. 
Our aim was to find out the correlation between FBS and OGTT and to find the 
threshold value of FBS, BMI for developing GDM.  
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There were totally 130 primigravida women and 140 multigravida women. Out 
of the 270 patients recruited in this study there was 45 patient belonging to the 
underweight category-BMI less than 18.5 kg/m2, BMI -18.5-24.9 kg/m2-147 patients, 
BMI-25-29.9 kg/m2-58 patients, BMI-30-34.9 kg/m2- 17 patients, >35 kg/m2-3 
patients,. The average BMI was 25. In the high BMI category >25kg/m2 there were 75 
patients out of which 7 patients had GDM. 19 patients were GGI positive. 49 patients 
had normal sugars based on DIPSI criteria. BMI p<0.01 which was statistically 
significant. 
In our study there were 11 patients in the underage category (less than 20 
yrs).209 patients were between 20-29yrs, 43 patients between 30-34 yrs and 7 patients 
greater than 35. Mean age of our patients was 25 yrs.  Patients with age >25 were 156 
patients of which 9 developed GDM, 26 developed GGI, 121 had normal blood sugars 
based on DIPSI criteria. Age was not statistically significant in our study.   
On evaluating for family history of  diabetes mellitus, patients with no family 
history were 222 patients, positive family history in 48 patients. Of the 48 patients 
who had positive family history of diabetes 5 developed GDM, while 11 developed 
GGI, 32 had normal sugars based on DIPSI criteria. Family history was not 
statistically significant in our study. 
Out of 270 patients, 14 patients developed GDM which is 5.2% of the total 
study population. 1 patient developed overt diabetes which is 0.3% of study 
population. 
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        Riskin-Mashiah et al.
42
 study had high predictive value of first trimester FBS, 
and consider FBS as a screening test and not as diagnostic test with a suggested cut off 
value. This study concluded that, The  FBS value lower than what is be considered as 
impaired fasting glucose, is associated with development of GDM. There is no clear 
cut off above which the risk of GDM is substantially increased. So for every 5 mg/dl 
increase in FBS or 3.5kg/m
2 
increase in BMI there was 1.5 fold increased risk. 
     In our study, First trimester FBS performance as a screening test for gestational 
diabetes mellitus was determined using receiver operating characteristic curve, and 
was suggestive of FBS>90mg/dl as threshold value for predicting the development of  
GDM with a sensitivity of  86.6% and a specificity of  52.1%% , positive predictive 
value of 9.6%, negative predictive value of 98.5%.  
When BMI performance was used as a screening test for gestational diabetes 
mellitus using receiver operating characteristic curve, was suggestive of BMI>24 was 
a good predictor of GDM with a sensitivity of  60% and specificity of 67.5%% , 
positive predictive value of 9.8%, negative predictive value of 96.6%. 
 
Area under curve was plotted to find the discriminatory power between FBS 
and BMI in diagnosis of GDM. AUC for FBS=0.69, AUC for BMI =0.63, thus FBS 
has little more discriminatory power in identifying GDM compared to BMI. 
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CONCLUSION 
        Early diagnosis of gestational diabetes mellitus (GDM) is important to improve 
for both maternal and fetal outcomes. 
The burden of diabetes in India is very high. It is an urgent need to establish 
screening and diagnostic procedure which is easy, understandable and simple. FBS 
measurement is a well tolerated and inexpensive routine examination
42
.FBS 
measurement has better test accuracy throughout the pregnancy
43,45
. First trimester 
fasting blood glucose value is an excellent test for determining the need to continue 
with the oral glucose tolerance test in the second trimester
45,46
. The hyperglycaemia 
and adverse pregnancy outcome study estimated that Fasting blood glucose 
measurement identifies about 50% of all affected women without an additional 1 and 
2 h OGTT values
47
 .  Though previously FBS was neglected as a screening test for 
GDM, in high risk population it provides simple, practical algorithm to screen for 
GDM
24
. Agarwal et al, using the value of FBS as a screening for GDM, is dependent 
on the diagnostic criteria which is used for the diagnosis of GDM . Riskin-Mashiah et 
al, has already reported that mild hyperglycemia in early pregnancy will lead to 
adverse pregnancy outcomes. So instead of subjecting all patient to a glucose load to 
do OGTT in first trimester which will aggrevate nausea, vomiting which is more 
prevalent in first trimester. Patients vomits during the test, requires OGTT to be 
repeated again on an another day and it is time consuming. So it is better to perform 
an easy, less time consuming, cost effective test that is fasting blood glucose. Our 
study also shows that FBS at first trimester will be helpful in the early prediction of 
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gestational diabetes mellitus and decreases the chance of developing GDM later in 
pregnancy.  Our study shows that  pregnant women with FBS >90 mg/dl are more 
likely to develop GDM later in pregnancy and more likely to develop adverse 
pregnancy outcome if no intervention is done for these patients.. Therefore, we 
suggest that women with Fasting blood glucose >90mg/dl who are more prone to 
develop GDM hence should be subjected to medical nutritional therapy.  
Early diagnosis and early intervention of diabetes is useful for improving 
pregnancy outcomes. In conclusion, , FBS measurement at first prenatal visit or at the 
time of first booking will be useful to screen for previously undiagnosed pre existing 
diabetes and also help to predict the development of GDM earlier. 
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APPENDIX 
PROFORMA 
      Patient Name: 
      OP NO: 
      IP NO: 
      Obstetric Score              : 
      Previous obstetric risk factors  : 
      Date of testing FBS                              : 
      1
st
 Trimester FBS value                      : 
      Gestational age during FBS            : 
      Category of 1
st
 Trimester FBS        :    1A / 1B / 1C 
      Date of testing GCT                             : 
      2
nd
 trimester 75gm GCT value        : 
      Gestational age during GCT           : 
      Category of 2
nd
 Trimester GCT       :    2A / 2B /2C   
      Correlation                                      :    Present / Absent 
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PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
  
   
  
  
I  (write name of the investigator(s) here), R.RESHMA SHRI,  am / are 
carrying out a study on the topic: EVALUATION OF FIRST TRIMESTER FASTING 
BLOOD GLUCOSE AS A PREDICTOR OF GESTATIONAL DIABETES MELLITUS 
 
as part of my research project being carried out under the aegis of the Department 
of:  Obstetrics and gynaecology 
  
My  research guide is: Dr. Latha Maheshwari 
  
The justification for this study is:  
This study will help to find the association of fasting blood sugar done at first 
trimester by comparing it with oral glucose tolerance (75g DIPSI criteria). Identifying 
the association positively will help early identification of GDM  which will prevent 
adverse pregnancy outcome and provide early intervention          
  
  
The objectives of this study are: 
  
To find association between diagnosis of GDM with fasting blood sugar 
compared with oral glucose tolerance  test ( 75g DIPSI criteri). 
  
  
 Sample size: 270. 
 
Study volunteers / participants are (specify population group & age group): antenatal patients  
 
Location: PSG HOSPITALS 
 
We request you to kindly cooperate with us in this study. We propose collect background 
information and other relevant details related to this study. We will be carrying out: 
  
Initial interview (specify approximate duration):_______5___ minutes. 
  
Data collected will be stored for a period of __15___ years. We will / will not use the data as part of 
another study. 
  
                                                                                                                                   
Blood sample collection: Specify quantity of blood being drawn: 2 ml. 
  
No. of times it will be collected: 1 
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Whether blood sample collection is part of routine procedure or for research (study) purpose:  
  
 Routine procedure       
  
Specify purpose, discomfort likely to be felt and side effect  for early identification of GDM, mild 
pain sensation at pricking site 
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  LIST OF ABBREVATIONS 
GDM gestational diabetes mellitus 
GCT glucose challenge test 
OGTT oral glucose tolerance test 
ADA american diabetic association 
WHO world health origination 
ACOG american college of obstetricians & gynecologist 
NDDG national diabetes data group 
TNF tumor necrosis factor 
FBS fasting blood sugar 
PPBS post prandial blood sugar 
BMI body mass index 
FPG fasting plasma glucose 
PPG post plasma glucose 
HAPO   hypergycaemia and adverse pregnancy outcome study 
ADA american diabetic association 
IADPSG   international association of diabetes in pregnancy study group 
DIPSI   diabetes in pregnancy study group in india 
NICU   neonatal intensive care unit 
ACHOIS  australian carbohydrate intolerance study in pregnant women 
LSCS     lower segment caesarian section 
 
  
 
 
 
 
 
 
 
 
 
 
Master chart 
S NO OP NO AGE LMP
OBST 
SCORE
RISK FACTORS FAMILY H/O DATE
FBS 
VALUE
GEST AGE DATE
GCT 
VALUE
GEST AGE
BMI 
VALUE
1 O14083767 23 10/7/2014 G2A1 NIL NIL 1/7/2015 73 12W+6D 3/18/2015 107 23W 21.8
2 O12036822 21 6/1/2014 G2P1L1 NIL NIL 8/29/2014 74 12W+3D 11/18/2014 105 24W 20
3 O14084051 19 9/14/2014 PRIMI NIL NIL 12/15/2014 76 12W+6D 2/5/2015 68 20W 20
4 O14051876 25 4/29/2014 PRIMI NIL NIL 8/4/2014 76 13W+5D 10/16/2014 84 24W 17.6
5 O14064179 22 7/27/2014 PRIMI NIL NIL 10/9/2014 77 10W+3D 12/11/2014 82 19W+2D 23
6 O14068813 22 7/5/2014 PRIMI NIL NIL 10/9/2014 77 13W+3D 12/11/2014 82 22W+3D 14
7 O11082733 28 4/6/2014 G2P1L1 SHO STATURE,PRE LSCS NIL 6/30/2014 77 11W+6D 10/6/2014 81 25W+6D 15.6
8 O14064874 21 8/1/2014 PRIMI NIL F-DM, 9/30/2014 79 8W+1D 1/17/2015 86 24W 16
9 O11008357 24 5/27/2014 G3P2L1(NND)1NIL NIL 8/13/2014 79 11W+1D 12/13/2014 107 28W+4D 36
10 O14059507 26 7/5/2014 PRIMI SHO STATURE NIL 10/1/2014 79 12W+3D 12/24/2014 86 24W+1D 25
11 O12071043 29 7/11/2014 G2P1L1 IDIO EPSO HYPOTHY F-THYROID 9/2/2014 79 7W+2D 12/19/2014 56 22W+5D 20
12 O14037525 30 5/4/2014 PRIMI NIL F-SHT, 8/2/2014 79 12W+5D 10/25/2014 97 24W+4D 17.6
13 O09031301 30 5/5/2014 G3P2L2 CHILDHOOD SEIZURE RX M-DM 7/29/2014 79 11W+6D 10/24/2014 109 24W+3D 20.5
14 O14054051 22 5/27/2014 PRIMI HYPOTHYROID NIL 8/16/2014 80 11W+4D 12/12/2014 111 28W+3D 19
15 O13018261 22 8/10/2014 PRIMI NIL NIL 11/7/2014 80 12W+5D 2/9/2015 89 26W+1D 16
16 O07082545 21 5/22/2014 G3P1L1A1 NIL NIL 7/22/2014 80 8W+4D 11/18/2014 77 25W+4D 17
17 O14053570 23 6/20/2014 PRIMI NIL NIL 8/14/2014 80 7W+5D 12/18/2014 120 25W+4D 25
18 O13070340 28 8/10/2014 PRIMI SUB HYPOTHY NIL 9/26/2014 81 6W+4D 2/4/2015 85 25W+2D 20
19 O14039693 23 4/13/2014 PRIMI NIL NIL 6/19/2014 81 9W+4D 9/25/2014 86 23W+3D 24
20 O14049398 29 5/3/2014 G2P1L1 NIL NIL 8/1/2014 81 12W+5D 10/31/2014 95 25W+4D 20.8
21 O14061522 26 6/13/2014 G3P1L0A1 PREV LSCS NIL 9/13/2014 81 12W+6D 12/10/2014 101 25W+5D 30
22 O14065104 24 8/1/2014 PRIMI NIL M-DM 9/22/2014 82 7W+1D 1/29/2015 94 25W+4D 21
23 O14066187 25 8/9/2014 G2P1L1 PRE LSCS M-DM 11/4/2014 82 12W+1D 2/6/2015 87 25W+2D 24
24 O14030802 25 9/1/2014 G2A0(ECTOPIC)1N L NIL 11/24/2014 82 12W 2/26/2015 117 25W+3D 17.7
25 O10102801 27 10/17/2014 PRIMI NIL F-DM 1/8/2015 82 11W+3D 3/3/2015 104 24W+2D 27
26 O13065582 32 8/7/2014 G2P1L1 NIL NIL 11/27/2014 82 15W 2/5/2015 87 25W+5D 22
27 O14037251 24 5/2/2014 PRIMI HYPOTHYROID NIL 6/27/2014 82 7W+5D 10/17/2014 95 23W+5D 17.6
28 O12002927 23 6/6/2014 G2P1L1A1 PRE LSCS NIL 8/4/2014 82 8W+2D 11/24/2014 88 24W+2D 20.9
29 O11027931 25 11/5/2014 G2P1L1 SUB CLINI HYPOTHY NIL 1/2/2015 82 8W 4/23/2015 86 23W+6D 20
30 O10102801 27 10/17/2014 PRIMI NIL OLD PTB 1/9/2015 82 11W+6D 3/3/2015 104 19W+5D 20.8
31 O14062029 25 7/4/2014 PRIMI SUB HYPOTHY NIL 10/10/2014 83 13W+6D 1/2/2015 72 25W+4D 19
32 O14066269 26 8/11/2014 G2A1 NIL F-DM, 10/19/2014 83 9W+4D 2/3/2015 93 24W+6D 29
33 O13082799 24 8/6/2014 G2A1 K/C/O RHD NIL 10/29/2014 83 11W+5D 1/30/2015 93 25W+1D 21
34 O14074458 20 9/12/2014 G2A1 NIL NIL 11/28/2014 83 11W 2/26/2015 98 24W 21
35 O14042761 21 4/9/2014 PRIMI NIL NIL 7/10/2014 83 12W+6D 10/6/2014 88 25W+3D 26
36 O10107936 25 4/7/2014 PRIMI ANAEMIA RX NIL 6/9/2014 83 8W+6D 10/6/2014 114 25W+5D 20
37 O11082611 30 8/27/2014 G3P1L1A1 NIL NIL 11/29/2014 84 12W+6D 2/19/2015 94 24W+6D 20
38 O12077799 22 8/14/2014 PRIMI NIL NIL 9/26/2014 84 6W 1/22/2015 73 23W 18
39 O14084022 17 9/12/2014 PRIMI NIL NIL 12/18/2014 84 13W+3D 3/2/2015 96 24W+2D 24
40 O09008030 33 8/18/2014 G2P1L1 PRE LSCS,HYPOTHYROID NIL 11/14/2014 84 12W+2D 2/10/2015 96 24W+6D 19
41 O14062735 21 6/10/2014 PRIMI NIL NIL 9/11/2014 84 12W+6D 12/11/2014 120 26W 22
42 O14064195 27 7/21/2014 PRIMI NIL NIL 9/18/2014 84 8W+2D 1/5/2015 94 24W 21.6
43 O14080298 19 9/6/2014 PRIMI NIL NIL 11/29/2014 84 12W 2/28/2015 89 25W 24
44 O14068069 29 7/9/2014 PRIMI NIL M-DM,SHT 10/9/2014 84 12W+6D 12/19/2014 84 23W 17
45 O14054046 21 6/29/2014 PRIMI NIL NIL 8/13/2014 84 6W+3D 12/17/2014 99 24W+1D 20.8
46 O14055221 25 5/19/2014 PRIMI NIL F-HEART DIS 8/16/2014 84 12W+4D 10/11/2014 110 19W+4D 24
47 O09014862 34 5/9/2014 G4P1L1A1(ECTO)1NIL F-DM 6/28/2014 84 6W+6D 10/11/2014 104 21W+6D 24
48 O14068731 23 7/17/2014 PRIMI SUB HYPOTHY F-DM, M -SHT 10/6/2014 85 11W+2D 1/19/2015 106 26W+1D 23
49 O14071403 25 8/11/2014 PRIMI NIL NIL 10/20/2014 85 9W+5D 1/29/2015 91 24W+1D 20
50 O14086922 18 10/21/2014 PRIMI NIL M-DM 12/31/2014 85 9W+6D 2/19/2015 126 17W+1D 25
51 O14086741 23 9/30/2014 PRIMI NIL NIL 12/24/2014 85 12W 3/4/2015 115 22W 20
52 O14069599 25 8/19/2014 PRIMI RH-VE NIL 10/17/2014 85 8W+1D 1/6/2015 115 20W 23
53 O14057897 25 6/22/2014 G2A1 BRO ASTH ,SUB HYPO NIL 9/15/2014 85 12W+1D 12/9/2014 115 24W+4D 21
54 O14077059 26 9/18/2014 PRIMI NIL NIL 12/12/2014 85 12W+1D 3/16/2015 132 25W+4D 21
55 O14075349 22 9/2/2014 PRIMI NIL NIL 12/1/2014 85 12W+6D 3/9/2015 93 26W+6D 20
56 O14077441 27 9/6/2014 PRIMI NIL NIL 11/17/2014 85 10W+2D 2/28/2015 92 25W 20
57 O14034513 26 4/16/2014 PRIMI NIL NIL 6/24/2014 85 9W+4D 10/6/2014 97 24W 18
58 O14053861 24 6/25/2014 PRIMI SUB HYPOTHYROID NIL 8/22/2014 85 8W 12/26/2014 91 25W+6D 29
59 O14037471 24 3/31/2014 PRIMI NIL NIL 6/7/2014 85 9W+5D 9/24/2014 126 25W 21
60 O14056713 21 6/6/2014 PRIMI NIL NIL 8/22/2014 85 10W+6D 12/5/2014 120 25W+3D 25
61 O14062034 22 6/14/2014 PRIMI NIL NIL 9/12/2014 85 12W+4D 11/11/2014 104 21W 20.8
62 O14048368 21 5/20/2014 PRIMI NIL NIL 8/16/2014 85 12W+3D 11/11/2014 88 24W+6D 20
63 O14087488 19 10/14/2014 PRIMI NIL NIL 1/3/2015 85 11W+3D 4/8/2015 120 25W+1D 23
64 O14078873 22 9/17/2014 PRIMI NIL NIL 11/24/2014 86 9W+3D 3/5/2015 92 24W 18
65 O14081918 19 9/15/2014 PRIMI NIL NIL 12/13/2014 86 12W+3D 3/4/2015 79 24W 17.8
66 O14066162 29 7/24/2014 PRIMI SUB THYROTOX F- CHD, M- DM 9/25/2014 86 8W+5D 1/19/2015 114 25W+1D 19.5
67 O14022752 22 7/19/2014 G3A2 P PRG SEV PRECLAMP M-SHT 9/26/2014 86 9W+5 D 1/19/2015 105 26W 22.9
68 O14077236 26 10/8/2014 PRIMI SUB HYPOTHY F-SHT, 11/17/2014 86 5W+4D 2/27/2015 100 20W+1D 28
69 O14057171 27 7/3/2014 PRIMI NIL F-DM,M-HT 8/30/2014 86 8W+1D 1/27/2015 128 29W+4D 27
70 O14064901 24 7/23/2014 G3P1L1A1 NIL NIL 9/20/2014 86 8W+1D 1/9/2015 93 24W 31
71 O14079789 28 9/24/2014 PRIMI SUB CLINI HYPOTHY NIL 11/29/2014 86 9W+2D 3/12/2015 131 24W+1D 18
72 O14077196 32 9/3/2014 G4P1L1A2 NIL NIL 11/15/2014 86 9W 2/23/2015 107 24W+5D 23.6
73 O12056767 17 8/23/2014 PRIMI SUB CLINI HYPOTHY NIL 11/15/2014 86 9W+3D 2/10/2015 136 24W+3D 23
74 O10088743 33 6/28/2014 G3P1L1A1 ANAEMIA RX F-HT 8/20/2014 86 7W+4D 12/24/2014 106 25W 21
75 O13032506 21 6/29/2014 G2P1L1 SEIZURE DISORDER NIL 8/23/2014 86 7W+5D 12/24/2014 85 25W 15
76 O14022605 24 3/28/2014 G2A1 NIL NIL 7/3/2014 86 12W+5D 10/3/2014 102 22W 27
77 O13003093 23 6/14/2014 G2P1L1 PRE-CS,RHD,MS&MR NIL 9/20/2014 86 13W+5D 12/31/2014 99 28W+2D 18
78 O14085990 25 9/18/2014 PRIMI SUB CLINI HYPOTHY M-DM,SHT 12/19/2014 86 12W+6D 3/19/2015 136 25W+5D 28
79 O14046038 21 5/27/2014 PRIMI NIL NIL 8/6/2014 86 10W 11/26/2014 108 26W 18.7
80 O14049880 23 5/28/2014 PRIMI NIL NIL 8/21/2014 86 12W 12/25/2014 123 24W 21
81 O14051171 21 5/2/2014 PRIMI NIL NIL 7/30/2014 86 12W+4D 11/7/2014 125 26W+5D 22.7
82 O03052446 30 10/8/2014 G2P1L1 NIL M-SHT 1/7/2015 86 12W+5D 3/6/2015 99 21W+2D 21
83 O14027235 30 7/12/2014 G4P2L2A1 2 PV LSCS, OVT HYPOTHY NIL 10/17/2014 87 13W+4D 1/13/2015 83 26W 18
84 O11075271 29 8/15/2014 G2P1L1 OVERT HYPOTHY NIL 10/20/2014 87 9W+1D 2/19/2015 98 26W+4D 17
85 O14074960 21 8/10/2014 PRIMI NIL F-DM 11/12/2014 87 12W+6D 1/21/2015 97 23W+1D 23
86 O14019035 26 7/20/2014 PRIMI FIBROID COM PREG F-DM 9/12/2014 87 7W+4D 2/25/2015 118 31W 27
87 O14069342 30 8/13/2014 G2P1L1 NIL NIL 10/13/2014 87 8W+3DAY 2/26/2015 88 27W+5D 34
88 O14023185 20 8/27/2014 G2A1 NIL CONG ANOMALI 11/19/2014 87 11W+5D 1/27/2015 93 21W+4D 20
89 O14065108 22 7/29/2014 PRIMI NIL M-RH 9/22/2014 87 7W+4D 1/19/2015 120 24W+4D 20.4
90 O14069469 23 8/26/2014 G2P1L1 PRE LSCS NIL 11/18/2014 87 11W+4D 1/20/2015 88 20W+5D 25.8
91 O14083789 27 9/13/2015 G4P3L3A0 ANAEMIA RX NIL 12/13/2014 87 12W+6D 2/28/2015 127 24W 20
92 O14078163 23 9/24/2014 PRIMI NIL F-DM 11/21/2014 87 8W+2D 2/20/2015 111 21W+2D 19
93 O05028564 23 9/24/2014 PRIMI NIL NIL 12/18/2014 87 12W+1D 3/5/2015 121 24W 20.5
94 O14066443 23 6/24/2014 G2P1L0 NIL NIL 9/25/2014 87 12W+6D 12/10/2014 83 24W+1D 26
95 O14062609 23 7/4/2014 G2P1L1 MILD ANAEMIA RX NIL 9/14/2014 87 10W 12/18/2014 61 23W+5D 15
96 O12043605 29 6/25/2014 G2P1L1 NIL NIL 9/1/2014 87 9W+4D 12/20/2014 97 25W+1D 16
97 O12009822 34 9/15/2014 G2P1L1 ULCER COLITIS NIL 11/7/2014 87 7W+3D 3/5/2015 121 24W+3D 18
98 O15002705 33 11/18/2014 G2A1 NIL M-DM 1/20/2015 87 9W 3/31/2015 117 19W 20.8
99 O14071859 23 8/14/2014 G2P1L1 NIL NIL 11/6/2014 88 11W+5D 3/5/2015 110 28W+3D 18
100 O14052045 23 6/8/2014 G2P1L1 PRE LSCS NIL 8/14/2014 88 9W+3D 12/18/2014 95 27W+2D 32.9
101 O14052245 24 6/13/2014 PRIMI NIL NIL 9/3/2014 88 11W+3D 12/17/2014 125 26W+2D 25
102 O14057229 27 7/1/2014 PRIMI SUB CLINI HYPOTHY NIL 8/27/2014 88 7W+6D 12/24/2014 111 24W+5D 25.7
103 O14046547 36 5/27/2014 G3A1 SUB CLINI HYPOTHY NIL 7/18/2014 88 7W+1D 12/12/2014 117 28W+3D 25.9
104 O09052109 24 5/28/2014 G3P1L1A1 NIL NIL 8/9/2014 88 10W+2D 11/27/2014 123 26W 26.8
105 O11078230 21 5/9/2014 G2P1L1 BRO ASTH ,EHPVO,ANA+ NIL 8/2/2014 88 11W+6D 11/8/2014 92 25W+6D 21.6
106 O14049080 22 5/5/2014 PRIMI NIL NIL 7/28/2014 88 11W+6D 11/6/2014 124 25W+5D 19.8
107 O14058826 22 7/10/2014 PRIMI NIL NIL 8/28/2014 88 6W+6D 12/22/2014 77 23W+3D 18.9
108 O14078751 27 9/30/2014 G4P1L1A2 PREV LSCS M-DM 11/24/2014 88 7W+5D 3/19/2015 134 24W+1D 18
109 O09102374 32 10/10/2014 G3P1L1A1 RH-VE NIL 1/7/2015 88 12W+4D 3/25/2015 82 23W+5D 19.7
110 O15003345 22 10/22/2014 G2P1L1 PREV LSCS NIL 1/21/2015 88 12W+6D 4/18/2015 123 25W+2D 23.9
111 O14082650 34 9/20/2014 G3P1L1A1 PREV LSCS NIL 12/17/2014 89 12W+2D 3/4/2015 102 23W+2D 20.7
112 O14065910 25 8/6/2014 PRIMI NIL M-DM 10/6/2014 89 8W+3D 1/12/2015 115 22W+3D 26
113 O14070793 24 8/11/2014 PRIMI NIL F-DM , M-SHT 11/20/2014 89 14W+2D 1/29/2015 111 24W 17
114 O14066346 25 7/1/2014 G4P1L1A2 NIL NIL 9/27/2014 89 12W+2D 1/21/2015 104 29W+6D 21
115 O14064136 26 7/28/2014 PRIMI SUBC HYPOTHY, BA NIL 9/18/2014 89 7W+1D 1/24/2015 102 25W+3D 21.1
116 O14015363 32 10/16/2014 G4P2L1 CHR SHT NIL 12/12/2014 89 8W 2/13/2015 105 17W 30.9
117 O11003630 26 8/7/2014 PRIMI ATT TAKEN NIL 10/7/2014 89 6W+4D 2/4/2015 111 24W 26.6
118 O14066445 27 8/11/2014 PRIMI NIL NIL 9/27/2014 89 6W+5D 1/31/2015 128 24W+3D 27
119 O14075434 27 9/11/2014 G2A1 SUBC HYPOTHY F- DM,BA 12/2/2014 89 11W+3D 2/3/2015 133 20W+3D 21
120 O13076523 25 8/15/2014 PRIMI NIL NIL 10/27/2014 89 10W+2D 1/31/2015 123 24W 24
121 O14071923 21 8/27/2014 PRIMI NIL F-DM 11/27/2014 89 12W+6D 2/2/2015 115 22W+3D 27
122 O14077366 33 9/1/2014 G2A1 NIL NIL 11/29/2014 89 12W+3D 2/10/2015 162 23W+2D 22.8
123 O14071415 32 9/7/2014 PRIMI NIL NIL 11/3/2014 89 8W 3/2/2015 87 24W+5D 21.6
124 O14069342 21 3/4/2014 G2P1L1 NIL NIL 10/13/2014 89 8W+5D 2/26/2015 88 28W+1D 21
125 O10091254 28 6/15/2014 PRIMI NIL NIL 7/31/2014 89 6W+4D 12/10/2014 72 25W+3D 22.9
126 O14055774 30 6/28/2014 G3P1L1A1 PRE LSCS NIL 9/3/2014 89 9W+3D 1/3/2015 148 26W+4D 24.6
127 O14069342 30 8/13/2014 G2P4 NIL NIL 10/13/2014 89 8W+5D 2/26/2015 88 28W+1D 33.7
128 O14079654 22 9/8/2014 PRIMI NIL NIL 12/2/2014 89 12W+1D 2/26/2015 81 24W+3D 22.5
129 O14062132 24 7/27/2014 PRIMI SUB CLINI HYPOTHY NIL 9/19/2014 89 7W+5D 12/9/2014 100 19W 25.6
130 O14066852 22 7/17/2014 G3P1L1A1 NIL NIL 10/17/2014 89 12W+6D 12/16/2014 85 21W+3D 16
131 O14047406 23 5/19/2014 PRIMI NIL NIL 7/17/2014 89 8W+2D 11/13/2014 108 24W+4D 19
132 O14049921 22 6/1/2014 G2P1L1 PRE LSCS,HYPOTHYROID NIL 7/28/2014 89 8W 11/27/2014 98 25W+3D 19.6
133 O14049913 23 5/29/2014 G2A1 NIL NIL 8/25/2014 89 12W+3D 11/27/2014 100 25W+6D 21.9
134 O10091254 28 6/15/2014 PRIMI NIL F-SHT, 7/13/2014 89 3W+4D 12/10/2014 72 25W+1D 24
135 O14083680 28 11/2/2014 PRIMI NIL NIL 1/21/2015 89 11W+2D 4/22/2015 135 24W+5D 26.9
136 O12054739 29 9/11/2014 G3P1L1A1 PREV LSCS NIL 11/10/2014 90 8W+3D 3/2/2015 89 24W+ 2D 19
137 O14076224 19 8/26/2014 PRIMI SUB HYPOTH, IDA NIL 11/17/2014 90 11W+4D 1/19/2015 101 20W+4D 20
138 O14070279 23 8/1/2014 PRIMI SUB HYPOTHY NIL 10/27/2014 90 12W+1D 1/31/2015 142 25W+5D 21.9
139 O07052728 24 8/4/2014 G2A1 NIL NIL 9/26/2014 90 7W+2D 1/29/2015 111 25W+1D 25
140 O14074723 25 9/7/2014 G4P1L1A2 PREV LSCS NIL 11/28/2014 90 11W+3D 3/3/2015 87 25W 21.5
141 O14059550 22 6/21/2014 PRIMI THYROID NIL 9/3/2014 90 10W+4D 12/6/2014 100 24W 17.5
142 O08058290 33 9/22/2014 G3P1L1A1 NIL NIL 11/26/2014 90 9W+1D 3/14/2015 100 24W+5D 19.5
143 O14089223 21 10/15/2014 PRIMI NIL M-DM 1/14/2015 90 12W+6D 3/14/2015 87 21W+6D 25
144 O14068379 24 8/12/2014 PRIMI NIL NIL 10/5/2014 90 7W+3D 2/7/2015 92 25W+1D 23
145 O12056881 30 3/4/2014 G3P1L1A1 NIL NIL 6/30/2014 90 12W+3D 10/1/2014 115 25W+4D 21
146 O14039195 27 4/8/2014 PRIMI HYPOTHYROID BO PARENT-DM 6/30/2014 90 11W+5D 10/6/2014 192 25W+3D 23.9
147 O14058786 35 7/7/2014 G3P2L2 HIV,PRE LSCS,ART16W NIL 10/6/2014 90 12W+5D 1/19/2015 136 27W+4D 23.7
148 O11039198 26 4/1/2015 G4P2L1A1(NND)1IL NIL 6/4/2014 90 8W+6D 9/20/2014 89 24W+3D 18
149 O07013795 30 6/15/2014 G3P2L2 SUB CLINI HYPOTHY NIL 8/11/2014 90 7W+6D 12/25/2014 147 27W+1D 25
150 O13073396 23 3/23/2014 G2A1 NIL NIL 6/4/2014 90 10W+3D 9/25/2014 108 26W+4D 20
151 O08010511 32 5/7/2014 G3P2L1(IUD)1PRE LSCS NIL 7/21/2014 90 10W+4D 11/17/2014 115 27W+2D 33
152 O14038400 24 4/23/2014 PRIMI NIL F-HT/M-HT,DM 6/16/2014 90 7W+5D 10/16/2014 112 24W+6D 15.8
153 O14036373 31 3/1/2014 PRIMI RHD-MILD MR&MVP NIL 6/2/2014 90 12W+6D 8/23/2014 118 24W+5D 21.6
154 O14048120 21 6/4/2014 PRIMI NIL NIL 7/31/2014 90 8W 12/4/2014 85 26W 20
155 O06040944 23 9/10/2014 PRIMI FIBROID COM PREG NIL 12/5/2014 90 12W+4D 2/26/2015 158 24W+1D 30
156 O13015574 33 11/1/2014 G3P1L1A1 NIL NIL 1/5/2015 90 9W+1D 4/6/2015 80 22W+2D 19.36
157 O08040710 29 10/14/2014 G2P1L1 PREV LSCS,BA NIL 1/12/2015 90 12W+5D 4/13/2015 94 25W+5D 21
158 O06019264 23 10/25/2014 PRIMI CHRON'S DISEASE NIL 1/19/2015 90 12W+1D 4/8/2015 85 23W+4D 24
159 O14076720 23 9/4/2014 PRIMI NIL M-DM 11/29/2014 91 11W+6D 2/26/2015 154 24W+5D 25.8
160 O14069246 25 8/29/2014 PRIMI NIL F-DM, M- DM 10/18/2014 91 7W 2/18/2015 89 24W+3D 28
161 O14074251 21 9/24/2014 G2A1 SUB HYPOTHY NIL 11/13/2014 91 7W 2/16/2015 107 20W+3D 18
162 O14052915 26 6/29/2014 PRIMI NIL NIL 9/22/2014 91 12W 12/29/2014 122 25W+6D 23
163 O08026327 28 8/27/2014 PRIMI NIL NIL 10/25/2014 91 8W+2D 2/11/2015 102 24W 26
164 O14059494 25 6/12/2014 PRIMI NIL NIL 9/17/2014 91 9W+2D 12/31/2014 106 24W+1D 20.7
165 O14067488 25 7/9/2014 G3P1L1A1 NIL NIL 10/7/2014 91 12W+4D 12/23/2014 143 24W 25
166 O14053327 27 6/2/2014 PRIMI BA NIL 8/28/2014 91 10W+3D 10/24/2014 88 20W+3D 18.8
167 O13055954 28 3/5/2014 PRIMI NIL NIL 6/5/2014 91 12W+6D 9/18/2014 167 17W+5D 20.8
168 O08075081 21 5/13/2014 G2P1L1 SUB CLINI HYPOTHY NIL 7/17/2014 91 9W+2D 11/10/2014 92 25W+6D 20
169 O10097829 24 6/22/2014 G1P1L1 SUB CLINI HYPOTHY NIL 8/19/2014 91 8W+1D 12/31/2014 79 27W+1D 20.8
170 O14071119 21 8/28/2014 PRIMI NIL NIL 11/24/2014 92 12W+2D 2/17/2015 111 24W+3D 21
171 O13001619 24 8/21/2014 G2P1L1 NIL NIL 11/10/2014 92 11W+2D 2/5/2015 92 24W 23
172 O12006882 26 8/7/2014 G2P1L1 NIL NIL 11/12/2014 92 13W+4D 2/2/2015 112 25W+1D 19
173 O14079716 26 9/18/2014 PRIMI NIL NIL 11/27/2014 92 9W+5D 2/2/2015 137 19W+3D 29
174 O14043130 25 5/7/2014 PRIMI SUB CLINI HYPOTHY NIL 7/2/2014 92 7W+6D 11/22/2014 78 28W+1D 18
175 O14056386 25 6/22/2014 PRIMI NIL NIL 8/21/2014 92 8W+2D 12/8/2014 109 23W+5D 22
176 O14039764 26 4/3/2014 PRIMI SUB CLINI HYPOTHY NIL 6/25/2014 92 11W+5D 10/8/2014 107 26W+4D 22
177 O14038184 25 3/27/2015 G3P2L1 PREV LSCS,BOH F-DM,HT,M-SHT 7/23/2014 92 12W+6D 11/12/2014 124 33W 33.9
178 O11079797 26 5/13/2014 G3P1L1A1 NIL NIL 7/15/2014 92 8W+5D 11/6/2014 115 25W 25
179 O11072597 27 9/10/2014 G4P2L2 NIL NIL 10/31/2014 92 7W+1D 3/15/2015 100 25W+5D 25.7
180 O14084277 20 10/8/2014 PRIMI NIL NIL 1/6/2015 92 12W+5D 3/27/2015 51 23W+3D 17.5
181 O15004434 25 10/30/2014 PRIMI NIL M-BA 1/24/2015 92 12W 4/2/2015 107 21W+6D 19.6
182 O14076244 25 8/18/2014 G2P1L2 NIL NIL 11/17/2014 92 12W+5D 1/26/2015 110 22W+2D 25.7
183 O11017102 28 3/14/2014 G2P1L1 BA NIL 6/9/2014 92 12W+1D 8/25/2014 114 27W+4D 18
184 O09056946 35 6/14/2014 G3P1L1A1 SUB CLINI HYPOTHY NIL 8/11/2014 93 8W+1D 11/13/2014 97 21W+4D 40
185 O11030247 24 5/29/2014 G3P1L1A1 NIL F-DM,SHT 7/24/2014 93 7W+6D 11/27/2014 161 25W+5D 29
186 O14037524 31 3/20/2014 PRIMI NIL NIL 6/18/2014 93 12W+5D 10/1/2014 73 27W+4D 21
187 O14019016 23 8/14/2014 G2A1 NIL NIL 10/14/2014 93 8W+4D 2/6/2015 86 24W+6D 24.1
188 O13027160 29 8/28/2014 G2P1L1 NIL NIL 10/21/2014 93 7W+4D 3/10/2015 125 27W+4D 25.4
189 O14084269 27 10/17/2014 PRIMI NIL NIL 1/9/2015 93 11W+5D 3/9/2015 112 20W+1D 23
190 O14078758 25 9/20/2014 G2A1 RH-VE F-DM 11/24/2014 93 9W 3/12/2015 99 24W+4D 18.8
191 O14081901 21 10/10/2014 PRIMI NIL NIL 1/10/2015 93 12W+6D 4/8/2015 88 25W+3D 24
192 O14037488 27 4/3/2014 PRIMI HYPERTHYROID NIL 6/7/2014 93 9W+1D 9/24/2015 113 24W+4D 21.6
193 O14021090 32 5/19/2014 G3P1L1A1 PREV LSCS NIL 7/12/2014 93 7W+4D 9/23/2014 83 17W+6D 26.5
194 O14038179 26 4/25/2014 G2P1L1 NIL NIL 7/7/2014 93 10W+2D 10/25/2014 75 25W+6D 21.6
195 O14016472 21 6/12/2014 PRIMI NIL NIL 9/5/2014 94 11W+6D 12/13/2014 94 26W 26.7
196 O07083000 33 8/30/2014 G3P1L1A1 PREV LSCS M-BA 11/22/2014 94 11W+6D 2/28/2015 131 25W+5D 23.6
197 O14063195 24 6/10/2014 G2A1 NIL NIL 9/13/2014 94 12W+4D 2/7/2015 119 33W+2D 27.2
198 O10084769 28 9/3/2014 G2P1L1 PREV LSCS M-DM 10/25/2014 94 7W+3D 2/27/2015 95 25W 21
199 O14071499 18 8/20/2014 G2P1L1 PREV LSCS NIL 10/27/2014 94 9W+4D 2/12/2015 82 24W+5D 26
200 O14077990 25 10/2/2014 PRIMI NIL GR-M-DM 12/2/2014 94 8W+3D 3/12/2015 99 22W+3D 24
201 O15004366 26 10/29/2014 PRIMI NIL NIL 1/28/2015 94 12W+5D 4/6/2015 125 22W+2D 16.4
202 O14084332 26 10/24/2014 PRIMI NIL F-DM,SHT 1/9/2015 94 10W+6D 3/13/2015 136 19W+6D 25.7
203 O14034532 30 3/29/2014 G2P1L1 PREV LSCS NIL 6/7/2014 94 9W+6D 9/12/2014 97 23W+4D 26
204 O13066264 27 4/15/2014 G2P1L0(NND)PRE LSCS NIL 6/5/2014 95 7W+1D 10/20/2014 121 26W+2D 19
205 O14054629 26 6/12/2014 PRIMI NIL NIL 8/14/2014 95 8W+6D 11/21/2014 95 23W+5D 18.5
206 O14055655 30 7/1/2014 G2P1L1 PRE LSCS NIL 8/22/2014 95 7W+1D 11/25/2014 80 20W+6D 17.9
207 O14057212 23 6/12/2014 PRIMI HYPOTHYROID NIL 8/28/2014 95 10W+5D 11/26/2014 128 23W+4D 26
208 O14056482 26 6/3/2014 PRIMI NIL F-DM,SHT 8/28/2014 95 12W+1D 12/8/2014 122 26W+4D 26.6
209 O14057803 28 6/15/2014 PRIMI NIL NIL 9/8/2014 95 11W+6D 12/15/2014 99 25W+6D 23
210 O14056521 31 6/19/2014 G3P1L1A1 PREV LSCS M-SEIZ,SIS-HYPO 8/21/2014 95 8W+56D 12/11/2014 97 24W+5D 18.6
211 O14054978 24 5/15/2014 PRIMI NIL NIL 8/15/2014 95 12W+6D 10/15/2014 89 21W+4D 22.9
212 O14052800 27 5/12/2014 PRIMI SUB HYPOTHY NIL 8/5/2014 95 11W+5D 11/10/2014 99 25W+3D 16.6
213 O14052817 24 8/3/2014 G2P1L1 HYPOTHYROID NIL 10/7/2014 95 9W 2/10/2015 97 27W 21
214 O05028564 23 9/24/2014 PRIMI NIL NIL 12/18/2014 95 11W+6D 3/5/2015 118 22W+6D 20.8
215 O15003319 22 10/19/2014 PRIMI NIL F-DM 1/19/2015 95 12W+6D 4/18/2015 100 25W+4D 15
216 O14024920 25 3/10/2014 PRIMI NIL NIL 6/18/2014 95 14W 9/20/2014 99 27W+3D 22.4
217 O13091558 25 4/18/2014 PRIMI NIL F-DM,SHT 6/16/2014 95 8W+1D 9/29/2014 129 23W 26.6
218 O15004901 22 12/5/2014 G3P2L1 NIL HUS-DM 1/30/2015 95 8W 4/7/2015 99 17W+4D 30.1
219 O14069961 26 12/20/2014 PRIMI NIL NIL 2/3/2015 95 6W+2D 4/17/2015 117 17W 23.3
220 O11018546 24 10/11/2014 G3P2L1 NIL NIL 1/7/2015 95 12W+3D 3/25/2015 92 23W+4D 17.6
221 O10049467 25 7/22/2014 G3P1L1A1 PRE LSCS,RH - VE NIL 9/12/2014 96 7W+2D 12/12/2014 97 20W+1D 31.2
222 O14060784 27 7/20/2014 G3P1L1A1 NIL BO PARENTS-DM 9/4/2014 96 6W+4D 12/11/2014 114 20W+3D 28
223 O14060827 19 7/11/2014 PRIMI HYPOTHYROID F-DM,M-DM 04-092014 96 7W+5D 1/8/2015 90 25W+4D 17.14
224 O14071634 28 9/9/2014 G2A1 HYPOTHYROID NIL 10/31/2014 96 7W+3D 2/17/2015 114 22W+5D 21.6
225 O14074927 29 8/20/2014 G2A1 MYOMA FOR FIB NIL 11/6/2014 96 10W+6D 2/11/2015 101 24W+5D 16.21
226 O13058135 27 9/20/2014 G2P1L1 PREV LSCS NIL 11/14/2014 96 8W+6D 3/3/2015 93 24W+3D 20.1
227 O14065968 23 7/28/2014 PRIMI SUB CLINI HYPOTHY NIL 9/25/2014 96 8W+1D 1/12/2015 146 23W+4D 25
228 O14077777 34 8/20/2014 G2P1L0 SUB CLINI HYPOTHY F-DM 11/20/2014 96 12W+5D 2/9/2015 143 25W 26
229 O14067337 26 7/20/2014 PRIMI NIL M-DM 10/19/2014 96 12W+6D 1/19/2015 120 25W+6D 20
230 O13069884 29 4/25/2014 PRIMI HYPOTHYROID F-SHT 7/17/2014 96 11W+5D 10/23/2014 139 25W+4D 29.1
231 O08050164 37 9/9/2014 G2P1L1 PREV LSCS NIL 12/16/2014 97 13W+5D 2/16/2015 97 22W+4D 19.7
232 O14026929 23 6/13/2014 G2P1L1 NIL NIL 9/8/2014 97 12W+1D 12/11/2014 215 25W+5D 18.99
233 O08051443 29 10/15/2014 PRIMI NIL F-DM 11/28/2014 97 6W 3/7/2015 125 20W+2D 17.8
234 O12014349 26 10/1/2014 G3P2L1 PREV 2 LSCS NIL 12/22/2014 97 11W+3D 3/16/2015 91 23+4D 23.4
235 O14069231 18 8/14/2014 PRIMI NIL NIL 10/16/2014 97 8W+6D 2/4/2015 98 24W+5D 22.18
236 O14072748 23 9/16/2014 PRIMI OVERT HYPOTHY F-DM,M-SHT 10/30/2014 97 6W+1D 3/12/2015 97 25W+2D 34.94
237 O10099264 31 4/26/2015 G3P1L1A1 NIL F-DM 6/20/2014 98 7W+5D 10/31/2014 140 26W+3D 18.1
238 O14064260 25 6/20/2014 PRIMI PCOD NIL 9/18/2014 98 12W+4D 12/19/2014 99 25W+5D 26.3
239 O14060449 23 6/22/2014 G2P1L1 NIL NIL 9/17/2014 98 12W+1D 12/17/2014 102 25W 21.1
240 O14020585 29 7/23/2014 G2A1 NIL NIL 9/14/2014 98 7W+3D 12/16/2014 161 20W+5D 31.6
241 O14042957 32 5/25/2014 G4P1LIA2 SUB CLINI HYPOTHY NIL 8/19/2014 98 12W 11/4/2014 88 23W 28.76
242 O14071668 26 8/31/2014 PRIMI NIL NIL 10/31/2014 98 8W+5D 2/24/2015 86 25W 19
243 O14054324 22 6/30/2014 PRIMI SUB CLINI HYPOTHY NIL 8/16/2014 98 6W+4D 1/2/2015 72 26W+2D 16.33
244 O11003032 30 9/3/2014 G3P1L1A1 NIL NIL 10/31/2014 98 8W+1D 2/2/2015 86 21W+5D 22.1
245 O14032184 20 6/11/2014 PRIMI NIL NIL 8/4/2014 99 7W+5D 12/4/2014 81 24W+6D 21.36
246 O14072850 27 9/1/2014 G2P1L1 SUB CLINI HYPOTHY NIL 11/3/2014 99 8W+5D 1/20/2015 91 19W+6D 30.1
247 O14040083 32 4/19/2014 G3P1L1A1 NIL F-DM 7/14/2014 99 12W 10/27/2014 107 26W+6D 22.93
248 O14085095 35 10/25/2014 PRIMI MYOMA,BOH NIL 12/23/2014 99 8W+2D 4/16/2015 113 24W+5D 33.3
249 O03023859 29 8/26/2014 G2P1L1 GTCS -SEIZURE NEROC NIL 10/28/2014 100 8W+5D 2/6/2015 93 23W+1D 24
250 O14060468 33 7/13/2014 PRIMI NIL NIL 9/3/2014 100 7W+1D 1/22/2015 103 27W+1D 23.6
251 O14052718 22 6/7/2014 PRIMI HYPOTHYROID NIL 9/1/2014 100 12W 12/4/2014 100 25W+4D 21.59
252 O14066837 25 7/5/2014 G3P1L1A1 PREV LSCS NIL 9/30/2014 100 12W 1/20/2015 98 28W 23
253 O14084346 29 10/15/2014 G2P1L0 PREV LSCS NIL 12/26/2014 100 10W 3/3/2015 98 19W+5D 31.6
254 O11048014 34 10/23/2014 G3P1L1A1 PRE LSCS M-DM,SHT, 1/17/2015 100 12W 3/6/2015 134 19W 27.4
255 O12092425 25 9/6/2014 G2P1L1 NIL NIL 12/17/2014 100 14W+2D 2/28/2015 74 24W+2D 35.61
256 O11079240 24 9/29/2014 G3P1L1A1 NIL NIL 12/24/2014 100 12W+1D 3/20/2015 122 24W+3D 21
257 O14055629 26 7/3/2014 PRIMI NIL M-DM,SHT 8/19/2014 101 6W+4D 12/16/2014 78 23W+3D 26.7
258 O14061786 36 7/17/2014 G2P1L1 PREV LSCS NIL 9/8/2014 101 7W+5D 1/4/2015 87 26W+5D 15.9
259 O10089515 20 7/15/2014 G3P1L1A1 PREV LSCS OVERT HYPOTHY 9/13/2014 101 8W+3D 1/17/2015 127 26W+3D 27.14
260 O12047507 23 8/7/2014 PRIMI NIL NIL 9/8/2014 102 4W+4D 12/2/2014 82 16W+3D 19.5
261 O09056872 26 10/29/2014 G2P1L1 RH-VE M-SHT 12/27/2014 102 8W+2D 4/22/2015 110 24W+6D 22.5
262 O14043550 32 5/16/2014 PRIMI NIL NIL 7/7/2014 104 7W+2D 11/13/2014 137 25W+4D 21.7
263 O14068278 32 8/19/2014 G2A1 HIV (+) F-DM 10/4/2014 104 6W+3D 11/11/2014 137 11W+3D 30.8
264 O14080074 25 9/4/2014 PRIMI NIL NIL 11/29/2014 104 12W 2/27/2015 98 24W+6D 19.5
265 O14033138 28 3/25/2014 G2A1 NIL F-SHT,M-DM 6/16/2014 104 11W+4D 8/21/2014 148 21W 21.3
266 O05020801 31 11/1/2014 G2P1L1 HYPOTHYROID NIL 1/8/2015 104 9W+4D 3/16/2015 106 19W+1D 23.5
267 O14082508 23 10/25/2014 PRIMI ANAEMIA RX NIL 1/20/2015 104 12W+1D 4/10/2015 106 23W+4D 15.6
268 O14021305 22 7/23/2014 PRIMI RH -VE BO PARENT-SHT 9/10/2014 105 10W+1D 11/7/2014 115 18W+3D 23.6
269 O08091633 35 5/1/2014 G5P1L1A3 SUB HYPOTHY,BOH NIL 6/13/2014 105 6W 11/13/2014 104 27W+5D 26.5
270 O10070759 33 11/4/2014 G4P1L1A2 BA NIL 2/4/2015 105 12W+5D 4/2/2015 84 21W+1D 27.54
